Progressive	O
Muscle	O
Cell	O
Delivery	O
as	O
a	O
Solution	O
for	O
Volumetric	O
Muscle	O
Defect	O
Repair	O

These	O
authors	O
contributed	O
equally	O
to	O
this	O
work	O
.	O

Reconstructing	O
functional	O
volumetric	O
tissue	O
in	O
vivo	O
following	O
implantation	O
remains	O
a	O
critical	O
challenge	O
facing	O
cell	O
-	O
based	O
approaches	O
.	O

Several	O
pre	O
-	O
vascularization	O
approaches	O
have	O
been	O
developed	O
to	O
increase	O
cell	O
viability	O
following	O
implantation	O
.	O

Structural	O
and	O
functional	O
restoration	O
was	O
achieved	O
in	O
a	O
preclinical	O
rodent	O
tissue	O
defect	O
;	O
however	O
,	O
the	O
approach	O
used	O
in	O
this	O
model	O
fails	O
to	O
repair	O
larger	O
(>	O
mm	O
)	O
defects	O
as	O
observed	O
in	O
a	O
clinical	O
setting	O
.	O

We	O
propose	O
an	O
effective	O
cell	O
delivery	O
system	O
utilizing	O
appropriate	O
vascularization	O
at	O
the	O
site	O
of	O
cell	O
implantation	O
that	O
results	O
in	O
volumetric	O
and	O
functional	O
tissue	O
reconstruction	O
.	O

Our	O
method	O
of	O
multiple	O
cell	O
injections	O
in	O
a	O
progressive	O
manner	O
yielded	O
improved	O
cell	O
survival	O
and	O
formed	O
volumetric	O
muscle	O
tissues	O
in	O
an	O
ectopic	O
muscle	O
site	O
.	O

In	O
addition	O
,	O
this	O
strategy	O
supported	O
the	O
reconstruction	O
of	O
functional	O
skeletal	O
muscle	O
tissue	O
in	O
a	O
rodent	O
volumetric	O
muscle	O
loss	O
injury	B-DS
model	O
.	O

Results	O
from	O
our	O
study	O
suggest	O
that	O
our	O
method	O
may	O
be	O
used	O
to	O
repair	O
volumetric	O
tissue	O
defects	O
by	O
overcoming	O
diffusion	O
limitations	O
and	O
facilitating	O
adequate	O
vascularization	O
.	O

Cell	O
-	O
based	O
therapies	O
in	O
tissue	O
engineering	O
(	O
TE	O
)	O
and	O
regenerative	O
medicine	O
(	O
RM	O
)	O
provide	O
promise	O
to	O
restore	O
normal	O
functions	O
of	O
damaged	O
and	O
injured	O
tissues	O
and	O
organs1	O
.	O

Such	O
strategies	O
include	O
cell	O
transplantation	O
and	O
implantation	O
of	O
engineered	O
tissue	O
constructs	O
,	O
where	O
efficient	O
cell	O
survival	O
following	O
implantation	O
is	O
a	O
critical	O
factor	O
to	O
the	O
success	O
.	O

Cell	O
-	O
based	O
strategies	O
have	O
been	O
used	O
successfully	O
in	O
preclinical	O
and	O
clinical	O
trials	O
to	O
treat	O
defects	O
in	O
avascular	O
tissues	O
,	O
such	O
as	O
cartilage	O
and	O
cornea	O
,	O
which	O
do	O
not	O
necessitate	O
blood	O
supply	O
to	O
maintain	O
cellular	O
viability	O
and	O
function	O
under	O
hypoxic	O
conditions234	O
.	O

Small	O
injuries	O
in	O
the	O
vascularized	O
tissues	O
that	O
correspond	O
to	O
a	O
few	O
microns	O
can	O
be	O
repaired	O
using	O
cell	O
-	O
based	O
approaches	O
because	O
the	O
implanted	O
cells	O
will	O
remain	O
viable	O
due	O
to	O
direct	O
transport	O
of	O
oxygen	O
and	O
nutrients	O
within	O
200	O
μm56789	O
from	O
host	O
vasculatures	O
as	O
well	O
as	O
diffusion	O
from	O
adjacent	O
host	O
blood	O
vessels	O
.	O

Skin	O
regeneration	O
has	O
been	O
achieved	O
using	O
cell	O
-	O
based	O
therapy	O
;	O
1011	O
however	O
,	O
efficient	O
treatment	O
of	O
defects	O
larger	O
than	O
millimeter	O
or	O
centimeter	O
scale	O
in	O
vascularized	O
tissues	O
and	O
organs	O
such	O
as	O
heart	O
,	O
liver	O
,	O
and	O
skeletal	O
muscle	O
remains	O
challenging	O
.	O

In	O
most	O
cases	O
,	O
repair	O
of	O
larger	O
tissue	O
defects	O
requires	O
implantation	O
of	O
large	O
,	O
volumetric	O
engineered	O
tissue	O
constructs	O
or	O
implantation	O
of	O
high	O
-	O
dose	O
cells121314	O
to	O
restore	O
normal	O
functions	O
.	O

Under	O
such	O
conditions	O
,	O
oxygen	O
transport	O
to	O
all	O
of	O
the	O
implanted	O
cells	O
is	O
difficult	O
.	O

In	O
particular	O
,	O
cells	O
located	O
in	O
the	O
center	O
of	O
thick	O
tissues	O
(	O
a	O
few	O
millimeter	O
scales	O
)	O
with	O
low	O
oxygen	O
concentration	O
will	O
become	O
necrotic	O
leading	O
to	O
failure	O
of	O
tissue	O
grafts	O
.	O

To	O
improve	O
the	O
cellular	O
viability	O
within	O
large	O
-	O
sized	O
defects	O
,	O
efficient	O
nutrient	O
and	O
oxygen	O
supply	O
are	O
necessary	O
;	O
11516	O
therefore	O
,	O
strategies	O
need	O
to	O
be	O
developed	O
for	O
volumetric	O
tissue	O
repair	O
to	O
improve	O
vascularization	O
,	O
which	O
will	O
have	O
a	O
positive	O
impact	O
on	O
cell	O
survival	O
.	O

To	O
date	O
,	O
several	O
strategies	O
have	O
been	O
developed	O
to	O
accelerate	O
vascularization	O
of	O
engineered	O
tissues	O
.	O

The	O
conventional	O
method	O
used	O
in	O
early	O
studies	O
promoted	O
vascularization	O
for	O
survival	O
of	O
the	O
implanted	O
cells	O
through	O
stimulation	O
of	O
in	O
vivo	O
microenvironments	O
at	O
the	O
time	O
of	O
implantation	O
.	O

To	O
stimulate	O
vascular	O
environments	O
,	O
pro	B-GP
-	I-GP
angiogenic	I-GP
factors	I-GP
such	O
as	O
vascular	B-GP
endothelial	I-GP
growth	I-GP
factors	I-GP
and	O
fibroblast	B-GP
growth	I-GP
factors	I-GP
were	O
incorporated	O
with	O
engineered	O
tissue	O
constructs	O
,	O
followed	O
by	O
the	O
implantation17	O
.	O

In	O
other	O
cases	O
,	O
exogenous	O
endothelial	O
stem	O
or	O
progenitor	O
cells	O
were	O
co	O
-	O
seeded	O
with	O
tissue	O
-	O
specific	O
cells	O
before	O
implantation1819	O
.	O

Although	O
incorporation	O
of	O
such	O
vascularization	O
cues	O
resulted	O
in	O
improved	O
vascularization	O
in	O
vivo	O
,	O
formation	O
of	O
new	O
blood	O
vessels	O
within	O
the	O
implant	O
site	O
was	O
too	O
slow	O
to	O
support	O
the	O
majority	O
of	O
implanted	O
cells7161920	O
.	O

Pre	O
-	O
fabrication	O
of	O
vascular	O
networks	O
within	O
engineered	O
tissue	O
constructs	O
during	O
in	O
vitro	O
cell	O
culture	O
of	O
the	O
seeded	O
scaffolds	O
provides	O
an	O
alternative	O
strategy	O
for	O
the	O
repair	O
of	O
a	O
volumetric	O
muscle	O
defect	O
.	O

Morphological	O
characterization	O
has	O
revealed	O
that	O
in	O
vitro	O
pre	O
-	O
vascularized	O
tissues	O
contained	O
well	O
-	O
organized	O
vascular	O
structures	O
and	O
could	O
accelerate	O
vascularization	O
time	O
by	O
providing	O
adequate	O
blood	O
supply	O
to	O
the	O
seeded	O
cells	O
.	O

Unfortunately	O
,	O
host	O
-	O
implant	O
anastomosis	O
of	O
in	O
vitro	O
pre	O
-	O
vascularized	O
tissues	O
usually	O
occurs	O
within	O
several	O
days	O
after	O
implantation	O
;	O
212223	O
thus	O
,	O
integration	O
of	O
reconstructed	O
tissue	O
with	O
the	O
host	O
was	O
inefficient	O
.	O

An	O
in	O
vivo	O
pre	O
-	O
vascularization	O
strategy	O
has	O
been	O
developed	O
to	O
fabricate	O
large	O
-	O
sized	O
,	O
vascularized	O
implantable	O
constructs	O
.	O

By	O
implanting	O
the	O
cell	O
-	O
seeded	O
scaffold	O
into	O
the	O
highly	O
vascularized	O
site	O
,	O
vascular	O
tissues	O
could	O
be	O
obtained	O
in	O
vivo	O
and	O
transferred	O
to	O
the	O
target	O
site24252627	O
.	O

In	O
another	O
study	O
,	O
the	O
polysurgery	O
approach	O
was	O
proposed	O
to	O
produce	O
thick	O
,	O
viable	O
myocardial	O
tissues	O
at	O
an	O
ectopic	O
site28	O
.	O

This	O
work	O
shows	O
that	O
repeated	O
cell	O
-	O
sheet	O
transplantation	O
at	O
time	O
intervals	O
of	O
1	O
–	O
2	O
days	O
can	O
generate	O
vascularized	O
cardiomyocyte	O
sheets	O
in	O
vivo	O
.	O

While	O
those	O
strategies	O
is	O
a	O
promising	O
approach	O
in	O
terms	O
of	O
addressing	O
volumetric	O
tissue	O
defects	O
,	O
several	O
issues	O
such	O
as	O
delayed	O
perfusion	O
,	O
numerous	O
surgical	O
interventions	O
,	O
and	O
inefficient	O
cell	O
grafting	O
within	O
the	O
vascularized	O
explanted	O
tissue	O
must	O
be	O
addressed	O
before	O
clinical	O
use15	O
.	O

Therefore	O
,	O
none	O
of	O
the	O
conventional	O
vascularization	O
strategies	O
is	O
appropriate	O
for	O
volumetric	O
tissue	O
repair	O
.	O

Towards	O
this	O
end	O
,	O
we	O
proposed	O
a	O
novel	O
and	O
simple	O
cell	O
delivery	O
method	O
that	O
enables	O
reconstruction	O
of	O
viable	O
,	O
large	O
tissues	O
in	O
vivo	O
for	O
restoration	O
of	O
volumetric	O
tissue	B-DS
injury	I-DS
through	O
an	O
efficient	O
vascularization	O
strategy	O
.	O

As	O
described	O
above	O
,	O
conventional	O
cell	O
-	O
based	O
approaches	O
for	O
volumetric	O
tissue	O
repair	O
are	O
limited	O
due	O
to	O
inefficient	O
blood	O
supply	O
for	O
implanted	O
cells	O
.	O

Therefore	O
,	O
we	O
hypothesized	O
that	O
multiple	O
injections	O
of	O
a	O
high	O
dose	O
of	O
cells	O
in	O
a	O
progressive	O
manner	O
would	O
maintain	O
cellular	O
viability	O
through	O
the	O
vascularization	O
process	O
when	O
compared	O
to	O
single	O
injection	O
of	O
the	O
same	O
number	O
of	O
cells	O
for	O
implantation	O
.	O

We	O
utilized	O
the	O
normal	O
vascularization	O
process	O
that	O
occurs	O
during	O
the	O
natural	O
regeneration	O
process	O
(	O
Fig	O
.	O
1	O
).	O

To	O
show	O
the	O
feasibility	O
of	O
restoring	O
functional	O
volumetric	O
tissues	O
in	O
the	O
defect	O
site	O
,	O
multiple	O
,	O
progressive	O
delivery	O
of	O
cells	O
was	O
performed	O
using	O
ectopic	O
cell	O
transplantation	O
in	O
a	O
subcutaneous	O
site	O
.	O

Appropriate	O
cell	O
delivery	O
parameters	O
such	O
as	O
cell	O
density	O
,	O
cell	O
injection	O
volume	O
,	O
and	O
time	O
interval	O
between	O
injections	O
were	O
tested	O
.	O

The	O
efficiency	O
of	O
volumetric	O
tissue	O
formation	O
was	O
compared	O
with	O
single	O
injection	O
of	O
the	O
same	O
number	O
of	O
cells	O
that	O
were	O
used	O
for	O
multiple	O
injections	O
.	O

Furthermore	O
,	O
this	O
cell	O
delivery	O
technique	O
using	O
C2C12	O
cells	O
and	O
human	B-OG
muscle	O
progenitor	O
cells	O
(	O
hMPCs	O
)	O
was	O
applied	O
to	O
a	O
rodent	O
volumetric	O
muscle	O
loss	O
(	O
VML	O
)	O
model	O
;	O
moreover	O
,	O
histological	O
and	O
functional	O
recovery	O
was	O
evaluated	O
to	O
determine	O
the	O
possibility	O
for	O
applications	O
to	O
treat	O
critical	O
-	O
size	O
muscle	O
defects	O
.	O

Results	O

Ectopic	O
muscle	O
construction	O
by	O
multiple	O
and	O
progressive	O
cell	O
injection	O

To	O
investigate	O
the	O
feasibility	O
of	O
restoring	O
volumetric	O
muscle	O
tissues	O
by	O
multiple	O
cell	O
injections	O
in	O
a	O
progressive	O
manner	O
,	O
C2C12	O
cells	O
were	O
subcutaneously	O
injected	O
in	O
athymic	O
mice	B-OG
,	O
and	O
the	O
volume	O
of	O
the	O
newly	O
formed	O
tissues	O
was	O
measured	O
at	O
pre	O
-	O
determined	O
injection	O
points	O
for	O
comparison	O
.	O

Multiple	O
-	O
cell	O
injections	O
with	O
one	O
week	O
interval	O
between	O
each	O
injection	O
resulted	O
in	O
an	O
increased	O
volume	O
of	O
the	O
implants	O
(	O
see	O
Supplementary	O
Fig	O
.	O

S2a	O
).	O

Quantitatively	O
,	O
increased	O
number	O
of	O
cell	O
injections	O
(	O
up	O
to	O
8	O
injections	O
)	O
correlated	O
with	O
an	O
increased	O
implant	O
volume	O
(	O
Fig	O
.	O
2a	O
).	O

Particularly	O
,	O
6	O
–	O
8	O
cell	O
injections	O
demonstrated	O
a	O
statically	O
significant	O
difference	O
(	O
ANOVA	O
and	O
post	O
hoc	O
Tukey	O
Test	O
)	O
when	O
compared	O
with	O
2	O
–	O
4	O
cell	O
injections	O
(*	O
P	O
<	O
0	O
.	O
0001	O
and	O
†	O
P	O
<	O
0	O
.	O
005	O
,	O
respectively	O
).	O

The	O
volumes	O
of	O
implants	O
in	O
all	O
multiple	O
,	O
progressive	O
cell	O
injected	O
groups	O
showed	O
a	O
significant	O
increase	O
compared	O
to	O
the	O
progressive	O
gel	O
only	O
-	O
injected	O
groups	O
(	O
ANOVA	O
,	O
‡	O
P	O
<	O
0	O
.	O
001	O
).	O

In	O
hematoxylin	O
and	O
eosin	O
(	O
H	O
&	O
E	O
)	O
and	O
masson	O
’	O
s	O
trichrome	O
(	O
MT	O
)	O
staining	O
images	O
(	O
see	O
Supplementary	O
Fig	O
.	O

S2b	O
),	O
increase	O
in	O
the	O
volume	O
of	O
reconstructed	O
tissue	O
formation	O
was	O
notable	O
between	O
2	O
and	O
4	O
cell	O
injections	O
,	O
but	O
no	O
significant	O
size	O
difference	O
was	O
observed	O
beyond	O
4	O
cell	O
injections	O
.	O

In	O
each	O
group	O
,	O
the	O
MT	O
images	O
demonstrated	O
that	O
the	O
newly	O
formed	O
tissue	O
structures	O
were	O
skeletal	O
muscle	O
fibers	O
as	O
confirmed	O
by	O
red	O
staining	O
within	O
the	O
implant	O
.	O

The	O
efficiency	O
of	O
progressive	O
cell	O
delivery	O
in	O
the	O
reconstruction	O
of	O
volumetric	O
tissue	O
was	O
determined	O
by	O
comparing	O
to	O
the	O
single	O
injection	O
of	O
cells	O
.	O

In	O
this	O
comparison	O
,	O
total	O
volume	O
(	O
1	O
.	O
2	O
ml	O
)	O
and	O
cell	O
number	O
was	O
set	O
to	O
be	O
equal	O
between	O
multiple	O
(	O
4	O
×	O
0	O
.	O
3	O
ml	O
per	O
injection	O
)	O
and	O
single	O
injection	O
(	O
1	O
.	O
2	O
ml	O
for	O
one	O
injection	O
);	O
furthermore	O
,	O
4	O
progressive	O
cell	O
injections	O
were	O
selected	O
as	O
more	O
than	O
4	O
injections	O
would	O
yield	O
an	O
unimplantable	O
volume	O
for	O
single	O
injection	O
to	O
the	O
animal	B-OG
.	O

The	O
volume	O
of	O
the	O
reconstructed	O
tissue	O
of	O
the	O
progressive	O
cell	O
injection	O
group	O
showed	O
approximately	O
4	O
-	O
fold	O
increase	O
as	O
compared	O
to	O
that	O
of	O
the	O
single	O
injection	O
of	O
cells	O
with	O
a	O
statistical	O
difference	O
(	O
Student	O
’	O
s	O
t	O
-	O
test	O
,	O
n	O
=	O
4	O
,	O
*	O
P	O
<	O
0	O
.	O
0001	O
)	O
(	O
Fig	O
.	O
2b	O
).	O

Interestingly	O
,	O
the	O
results	O
of	O
green	B-GP
fluorescent	I-GP
protein	I-GP
(	O
GFP	B-GP
)	O
immunostaining	O
revealed	O
that	O
the	O
progressively	O
-	O
injected	O
C2C12	O
cells	O
contributed	O
to	O
the	O
formation	O
of	O
muscle	O
fibers	O
in	O
vivo	O
as	O
confirmed	O
by	O
GFP	B-GP
+	O
muscle	O
fiber	O
-	O
like	O
structures	O
within	O
the	O
reconstructed	O
tissue	O
(	O
Fig	O
.	O
2c	O
),	O
while	O
a	O
few	O
GFP	B-GP
+	O
C2C12	O
cells	O
scattered	O
in	O
the	O
implant	O
were	O
found	O
in	O
the	O
single	O
injection	O
.	O

This	O
result	O
demonstrates	O
that	O
multiple	O
,	O
progressive	O
cell	O
injections	O
are	O
more	O
effective	O
than	O
single	O
injection	O
for	O
the	O
formation	O
of	O
a	O
volumetric	O
muscle	O
-	O
like	O
structure	O
at	O
a	O
muscle	O
ectopic	O
site	O
.	O

Efficient	O
muscle	O
cell	O
survival	O
,	O
muscle	O
tissue	O
formation	O
,	O
and	O
vascularization	O
by	O
progressively	O
injected	O
cells	O

To	O
examine	O
the	O
muscle	O
tissue	O
formation	O
and	O
maturation	O
of	O
progressively	O
injected	O
C2C12	O
cells	O
,	O
myosin	B-GP
heavy	I-GP
chain	I-GP
(	O
MHC	B-GP
)	O
immunostaining	O
was	O
performed	O
on	O
the	O
reconstructed	O
tissue	O
.	O

Throughout	O
the	O
reconstructed	O
tissue	O
,	O
viable	O
MHC	B-GP
+	O
muscle	O
fiber	O
-	O
like	O
structures	O
and	O
cells	O
were	O
clearly	O
visualized	O
as	O
indicated	O
by	O
the	O
dotted	O
lines	O
(	O
Fig	O
.	O
3b	O
,	O
first	O
row	O
).	O

In	O
the	O
area	O
of	O
the	O
early	O
1st	O
injection	O
(	O
inner	O
site	O
of	O
the	O
implant	O
),	O
a	O
number	O
of	O
MHC	B-GP
+	O
multi	O
-	O
nucleated	O
muscle	O
fibers	O
were	O
observed	O
,	O
while	O
a	O
few	O
MHC	B-GP
+	O
cells	O
with	O
pre	O
-	O
matured	O
structures	O
were	O
found	O
in	O
the	O
area	O
of	O
the	O
last	O
4th	O
injection	O
(	O
outer	O
site	O
).	O

The	O
observable	O
difference	O
in	O
muscle	O
maturation	O
demonstrates	O
that	O
multiple	O
cell	O
injections	O
performed	O
in	O
a	O
progressive	O
manner	O
allows	O
muscle	O
cell	O
survival	O
,	O
muscle	O
formation	O
,	O
and	O
maturation	O
of	O
the	O
injected	O
cells	O
in	O
an	O
ectopic	O
site	O
.	O

Vascularization	O
of	O
the	O
injected	O
C2C12	O
cells	O
in	O
a	O
timely	O
manner	O
is	O
a	O
critical	O
factor	O
to	O
re	O
-	O
create	O
volumetric	O
muscle	O
tissue	O
by	O
providing	O
an	O
adequate	O
blood	O
supply	O
to	O
the	O
grafted	O
cells	O
.	O

We	O
hypothesized	O
that	O
each	O
injection	O
of	O
cells	O
in	O
a	O
progressive	O
manner	O
would	O
promote	O
efficient	O
vascularization	O
with	O
the	O
host	O
.	O

To	O
test	O
the	O
hypothesis	O
,	O
double	O
staining	O
of	O
GFP	B-GP
and	O
von	B-GP
Willebrand	I-GP
factor	I-GP
(	O
vWF	B-GP
)	O
was	O
performed	O
to	O
determine	O
whether	O
the	O
injected	O
GFP	B-GP
+	O
C2C12	O
cells	O
are	O
localized	O
with	O
vWF	B-GP
+	O
blood	O
vessels	O
for	O
improved	O
cell	O
survival	O
.	O

The	O
double	O
fluorescent	O
imaging	O
showed	O
that	O
GFP	B-GP
+	O
C2C12	O
cells	O
are	O
present	O
throughout	O
the	O
injected	O
area	O
and	O
are	O
localized	O
within	O
100	O
–	O
200	O
μm	O
of	O
vWF	B-GP
+	O
blood	O
vessels	O
(	O
Fig	O
.	O
3b	O
,	O
second	O
row	O
).	O

This	O
finding	O
suggests	O
that	O
progressively	O
injected	O
cells	O
remained	O
viable	O
along	O
with	O
newly	O
-	O
formed	O
vasculatures	O
in	O
the	O
injected	O
area	O
up	O
to	O
4	O
weeks	O
after	O
injection	O
.	O

Vascularization	O
and	O
neuronal	O
ingrowth	O
by	O
progressive	O
cell	O
injections	O

To	O
compare	O
vascularization	O
outcomes	O
between	O
the	O
progressive	O
and	O
single	O
cell	O
injections	O
,	O
vWF	B-GP
/	O
α	B-GP
-	I-GP
smooth	I-GP
muscle	I-GP
actin	I-GP
(	O
α	B-GP
-	I-GP
SMA	I-GP
)	O
immunostaining	O
was	O
performed	O
in	O
each	O
group	O
(	O
Fig	O
.	O
3a	O
,	O
b	O
).	O

Quantitatively	O
,	O
new	O
blood	O
vessel	O
formation	O
and	O
vascular	O
maturation	O
were	O
assessed	O
by	O
counting	O
the	O
number	O
of	O
vWF	B-GP
+	O
vessels	O
(	O
per	O
field	O
),	O
and	O
calculating	O
the	O
area	O
of	O
vWF	B-GP
+	O
vessels	O
(	O
μm2	O
per	O
field	O
),	O
maturation	O
index	O
(%)	O
and	O
percentage	O
of	O
different	O
vessel	O
sizes	O
(	O
Fig	O
.	O
3c	O
,	O
n	O
=	O
4	O
,	O
9	O
–	O
12	O
fields	O
per	O
each	O
sample	O
).	O

The	O
number	O
and	O
area	O
of	O
vWF	B-GP
+	O
vessels	O
(/	O
field	O
)	O
in	O
the	O
progressive	O
injection	O
samples	O
significantly	O
increased	O
,	O
as	O
compared	O
to	O
that	O
of	O
the	O
single	O
cell	O
injection	O
group	O
(	O
Fig	O
.	O
3c	O
-	O
i	O
,	O
c	O
-	O
ii	O
,	O
Student	O
’	O
s	O
t	O
-	O
test	O
,	O
*	O
P	O
<	O
0	O
.	O
05	O
).	O

However	O
,	O
the	O
level	O
of	O
vascular	O
maturation	O
showed	O
no	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
(	O
Fig	O
.	O
3c	O
-	O
iii	O
,	O
Student	O
’	O
s	O
t	O
-	O
test	O
,	O
P	O
>	O
0	O
.	O
05	O
).	O

The	O
majority	O
of	O
blood	O
vessels	O
observed	O
in	O
the	O
single	O
cell	O
injection	O
group	O
was	O
less	O
than	O
200	O
μm	O
in	O
diameter	O
,	O
whereas	O
a	O
higher	O
percentage	O
of	O
larger	O
blood	O
vessels	O
greater	O
than	O
500	O
μm	O
in	O
diameter	O
was	O
present	O
in	O
the	O
progressive	O
cell	O
injection	O
group	O
(	O
Fig	O
.	O
3c	O
-	O
iv	O
,	O
Student	O
’	O
s	O
t	O
-	O
test	O
,	O
*	O
P	O
<	O
0	O
.	O
05	O
).	O

These	O
results	O
indicate	O
that	O
multiple	O
,	O
progressive	O
cell	O
injection	O
is	O
an	O
effective	O
cell	O
delivery	O
method	O
to	O
achieve	O
vascularized	O
volumetric	O
muscle	O
structure	O
.	O

To	O
examine	O
whether	O
vascularization	O
and	O
maturation	O
during	O
progressive	O
cell	O
injections	O
occur	O
in	O
a	O
normal	O
and	O
physiological	O
manner	O
,	O
blood	O
vessels	O
formation	O
of	O
progressively	O
injected	O
areas	O
(	O
the	O
1st	O
,	O
2nd	O
–	O
3rd	O
,	O
and	O
4th	O
injected	O
areas	O
)	O
was	O
quantified	O
by	O
using	O
vWF	B-GP
/	O
α	B-GP
-	I-GP
SMA	I-GP
immunostaining	O
images	O
(	O
Fig	O
.	O
3d	O
,	O
n	O
=	O
4	O
,	O
3	O
–	O
5	O
fields	O
per	O
each	O
area	O
in	O
each	O
sample	O
).	O

Large	O
and	O
matured	O
vessels	O
(	O
vWF	B-GP
+	O
α	B-GP
-	I-GP
SMA	I-GP
+)	O
were	O
observed	O
in	O
both	O
areas	O
surrounding	O
the	O
1st	O
injection	O
site	O
and	O
the	O
2nd	O
–	O
3rd	O
injection	O
(	O
Fig	O
.	O
3b	O
,	O
third	O
row	O
).	O

More	O
immature	O
vessels	O
(	O
vWF	B-GP
+	O
α	B-GP
-	I-GP
SMA	I-GP
−)	O
are	O
visualized	O
in	O
the	O
area	O
of	O
the	O
4th	O
injection	O
(	O
last	O
injection	O
)	O
than	O
any	O
of	O
the	O
other	O
sites	O
.	O

The	O
site	O
of	O
the	O
4th	O
injection	O
showed	O
the	O
highest	O
number	O
of	O
vWF	B-GP
+	O
blood	O
vessels	O
and	O
the	O
lowest	O
area	O
of	O
vWF	B-GP
+	O
vessels	O
with	O
a	O
significant	O
difference	O
(	O
Fig	O
.	O
3d	O
-	O
I	O
,	O
d	O
-	O
ii	O
,	O
ANOVA	O
,	O
*	O
P	O
<	O
0	O
.	O
05	O
with	O
the	O
1st	O
injection	O
,	O
†	O
P	O
<	O
0	O
.	O
05	O
with	O
the	O
2nd	O
injection	O
,	O
Tukey	O
test	O
),	O
which	O
demonstrated	O
more	O
newly	O
formed	O
small	O
-	O
sized	O
capillaries	O
at	O
the	O
injection	O
site	O
when	O
compared	O
to	O
that	O
of	O
the	O
earlier	O
injected	O
sites	O
.	O

In	O
terms	O
of	O
the	O
degree	O
of	O
blood	O
vessel	O
maturation	O
,	O
the	O
1st	O
injection	O
site	O
(	O
inner	O
site	O
)	O
showed	O
highest	O
maturation	O
index	O
compared	O
with	O
the	O
other	O
three	O
sites	O
(	O
Fig	O
.	O
3d	O
-	O
iii	O
,	O
ANOVA	O
,	O
*	O
P	O
<	O
0	O
.	O
05	O
with	O
the	O
1st	O
injection	O
,	O
†	O
P	O
<	O
0	O
.	O
05	O
with	O
the	O
2nd	O
injection	O
,	O
Tukey	O
test	O
).	O

These	O
quantitative	O
results	O
correlate	O
with	O
the	O
percentage	O
of	O
blood	O
vessels	O
as	O
a	O
function	O
of	O
blood	O
vessels	O
size	O
(	O
Fig	O
.	O
3d	O
-	O
iv	O
).	O

This	O
finding	O
is	O
consistent	O
with	O
normal	O
angiogenesis	O
that	O
can	O
be	O
found	O
in	O
another	O
study29	O
.	O

In	O
contrast	O
,	O
inner	O
area	O
of	O
implants	O
constructed	O
by	O
single	O
cell	O
injection	O
showed	O
the	O
lowest	O
area	O
of	O
vWF	B-GP
+	O
vessels	O
,	O
and	O
there	O
were	O
no	O
significant	O
differences	O
in	O
number	O
,	O
maturation	O
and	O
percentage	O
of	O
blood	O
vessels	O
among	O
inner	O
,	O
middle	O
,	O
outer	O
areas	O
(	O
see	O
Supplementary	O
Fig	O
.	O

S3	O
).	O

In	O
addition	O
,	O
neuronal	O
ingrowth	O
,	O
which	O
is	O
a	O
critical	O
cellular	O
event	O
in	O
functional	O
muscle	O
regeneration	O
,	O
appeared	O
to	O
occur	O
in	O
a	O
normal	O
condition	O
.	O

The	O
progressive	O
cell	O
injection	O
facilitated	O
recruitment	O
of	O
Neurofilament	B-GP
(	O
NF	B-GP
)+	O
peripheral	O
nerves	O
at	O
each	O
injection	O
site	O
(	O
Fig	O
.	O
3b	O
,	O
lowest	O
row	O
).	O

These	O
results	O
showed	O
that	O
multiple	O
cell	O
injections	O
in	O
a	O
progressive	O
manner	O
maintained	O
viability	O
of	O
the	O
delivered	O
cells	O
within	O
the	O
muscle	O
ectopic	O
site	O
while	O
single	O
injection	O
did	O
not	O
;	O
furthermore	O
,	O
the	O
vascularization	O
and	O
neuronal	O
ingrowth	O
were	O
observed	O
that	O
facilitated	O
the	O
volumetric	O
skeletal	O
muscle	O
construct	O
in	O
vivo	O
.	O

Improved	O
structural	O
and	O
functional	O
recovery	O
of	O
critical	O
defect	O
in	O
TA	O
muscle	O
by	O
progressive	O
cell	O
injection	O

Encouraged	O
by	O
promising	O
outcomes	O
in	O
the	O
ectopic	O
implantation	O
study	O
,	O
we	O
applied	O
the	O
progressive	O
cell	O
delivery	O
method	O
to	O
restore	O
muscle	O
function	O
of	O
the	O
injured	O
skeletal	O
muscle	O
.	O

To	O
test	O
the	O
possibility	O
,	O
a	O
volumetric	O
muscle	O
defect	O
in	O
a	O
critical	O
-	O
size	O
was	O
utilized	O
to	O
test	O
the	O
efficiency	O
of	O
the	O
progressive	O
cell	O
delivery	O
method	O
.	O

As	O
a	O
volumetric	O
muscle	O
defect	O
model	O
,	O
30	O
%	O
of	O
original	O
tibialis	O
anterior	O
(	O
TA	O
)	O
muscle	O
mass	O
was	O
excised	O
and	O
this	O
level	O
of	O
muscle	O
loss	O
is	O
incapable	O
of	O
fully	O
restoring	O
the	O
TA	O
muscle	O
for	O
several	O
months	O
without	O
any	O
treatment	O
.	O

Therapeutic	O
efficacy	O
of	O
progressive	O
cell	O
injections	O
was	O
evaluated	O
by	O
anatomical	O
and	O
functional	O
analysis	O
(	O
n	O
=	O
4	O
per	O
each	O
group	O
).	O

Grossly	O
,	O
the	O
TA	O
muscle	O
of	O
progressive	O
injections	O
was	O
harvested	O
at	O
4	O
weeks	O
after	O
first	O
injection	O
and	O
showed	O
better	O
TA	O
anatomy	O
than	O
no	O
treatment	O
(	O
defect	O
only	O
),	O
gel	O
only	O
,	O
or	O
single	O
injection	O
group	O
(	O
see	O
Supplementary	O
Fig	O
.	O

S4	O
).	O

As	O
observed	O
in	O
the	O
gross	O
images	O
,	O
single	O
injection	O
of	O
C2C12	O
recovered	O
the	O
defected	O
TA	O
muscle	O
by	O
a	O
1	O
.	O
3	O
-	O
fold	O
increase	O
in	O
TA	O
muscle	O
mass	O
compared	O
with	O
no	O
treatment	O
and	O
gel	O
only	O
injection	O
group	O
(	O
Fig	O
.	O
4a	O
).	O

The	O
ratio	O
of	O
the	O
treated	O
-	O
to	O
contralateral	O
TA	O
muscle	O
mass	O
of	O
the	O
progressive	O
C2C12	O
injection	O
group	O
showed	O
a	O
1	O
.	O
3	O
-	O
fold	O
increase	O
compared	O
to	O
that	O
of	O
the	O
single	O
C2C12	O
injection	O
group	O
with	O
a	O
significant	O
difference	O
(	O
ANOVA	O
and	O
Tukey	O
test	O
,	O
§	O
P	O
<	O
0	O
.	O
017	O
)	O
(	O
Fig	O
.	O
4a	O
).	O

Interestingly	O
,	O
the	O
increased	O
muscle	O
mass	O
correlates	O
with	O
improved	O
muscle	O
function	O
.	O

Tetanic	O
muscle	O
force	O
of	O
the	O
progressive	O
C2C12	O
muscle	O
injection	O
group	O
showed	O
a	O
2	O
-	O
fold	O
increase	O
,	O
as	O
compared	O
to	O
that	O
of	O
the	O
single	O
C2C12	O
injection	O
group	O
(	O
ANOVA	O
and	O
Tukey	O
test	O
,	O
§	O
P	O
<	O
0	O
.	O
016	O
).	O

Muscle	O
function	O
improvement	O
demonstrated	O
by	O
the	O
progressive	O
C2C12	O
injections	O
was	O
approximately	O
42	O
%	O
of	O
normal	O
TA	O
muscle	O
.	O

The	O
multiple	O
progressive	O
injections	O
of	O
hMPCs	O
also	O
showed	O
a	O
similar	O
pattern	O
,	O
in	O
terms	O
of	O
muscle	O
function	O
improvement	O
.	O

When	O
compared	O
with	O
the	O
single	O
hMPC	O
injection	O
,	O
the	O
progressive	O
hMPC	O
injections	O
facilitated	O
a	O
1	O
.	O
5	O
-	O
and	O
2	O
.	O
6	O
-	O
fold	O
increase	O
in	O
muscle	O
mass	O
and	O
function	O
,	O
respectively	O
(	O
Student	O
’	O
s	O
t	O
-	O
test	O
,	O
*	O
P	O
<	O
0	O
.	O
05	O
)	O
(	O
Fig	O
.	O
4c	O
).	O

Progressively	O
injected	O
hMPCs	O
in	O
the	O
TA	O
muscle	O
showed	O
39	O
%	O
restoration	O
of	O
the	O
muscle	O
function	O
,	O
as	O
compared	O
with	O
normal	O
TA	O
muscle	O
.	O

Improved	O
functional	O
outcome	O
by	O
both	O
cell	O
types	O
was	O
evidenced	O
by	O
histological	O
analysis	O
.	O

Based	O
on	O
the	O
H	O
&	O
E	O
images	O
,	O
TA	O
muscle	O
thicknesses	O
of	O
progressive	O
C2C12	O
and	O
hMPC	O
injection	O
groups	O
were	O
1	O
.	O
6	O
-	O
and	O
1	O
.	O
2	O
-	O
fold	O
higher	O
than	O
that	O
of	O
single	O
injections	O
with	O
a	O
statistical	O
difference	O
(	O
ANOVA	O
and	O
Tukey	O
test	O
,	O
§	O
P	O
<	O
0	O
.	O
001	O
and	O
Student	O
’	O
s	O
t	O
-	O
test	O
,	O
*	O
P	O
<	O
0	O
.	O
003	O
)	O
(	O
Fig	O
.	O
4b	O
,	O
d	O
),	O
respectively	O
.	O

To	O
evaluate	O
the	O
level	O
of	O
fibrosis	O
in	O
muscle	O
tissue	O
,	O
collagen	B-GP
I	I-GP
/	O
MHC	B-GP
immunostaining	O
was	O
performed	O
.	O

The	O
percentage	O
of	O
collagen	B-GP
I	I-GP
+	O
area	O
of	O
inner	O
TA	O
and	O
outer	O
TA	O
was	O
quantified	O
(	O
n	O
=	O
4	O
,	O
3	O
random	O
fields	O
per	O
each	O
area	O
in	O
each	O
sample	O
)	O
(	O
see	O
Supplementary	O
Fig	O
.	O

S5	O
).	O

In	O
all	O
groups	O
,	O
severe	O
fibrosis	O
was	O
observed	O
in	O
the	O
outer	O
area	O
of	O
injection	O
sites	O
,	O
when	O
compared	O
with	O
the	O
inner	O
TA	O
.	O

However	O
,	O
the	O
progressive	O
injection	O
group	O
,	O
regardless	O
of	O
the	O
cell	O
types	O
,	O
resulted	O
in	O
reduced	O
levels	O
of	O
fibrosis	O
,	O
as	O
compared	O
with	O
the	O
single	O
cell	O
injection	O
group	O
in	O
both	O
the	O
inner	O
TA	O
and	O
outer	O
TA	O
(	O
ANOVA	O
and	O
Tukey	O
test	O
,	O
P	O
<	O
0	O
.	O
05	O
).	O

Particularly	O
,	O
the	O
degree	O
of	O
fibrosis	O
of	O
the	O
inner	O
area	O
in	O
the	O
progressive	O
C2C12	O
injection	O
group	O
was	O
comparable	O
to	O
normal	O
TA	O
muscle	O
with	O
no	O
statistical	O
difference	O
(	O
ANOVA	O
and	O
Tukey	O
test	O
,	O
*	O
P	O
>	O
0	O
.	O
997	O
).	O

Overall	O
,	O
multiple	O
cell	O
injections	O
in	O
a	O
progressive	O
manner	O
is	O
an	O
effective	O
cell	O
delivery	O
method	O
in	O
term	O
of	O
anatomical	O
and	O
functional	O
improvement	O
of	O
volumetric	O
muscle	O
defect	O
,	O
when	O
compared	O
with	O
no	O
treatment	O
,	O
cell	O
delivery	O
vehicle	O
only	O
and	O
single	O
delivery	O
of	O
same	O
cell	O
number	O
.	O

Muscle	O
fiber	O
formation	O
of	O
progressively	O
injected	O
cells	O
and	O
vascularization	O
and	O
neuronal	O
ingrowth	O

To	O
examine	O
whether	O
each	O
progressive	O
cell	O
injection	O
can	O
efficiently	O
deliver	O
the	O
infused	O
cells	O
to	O
occupy	O
the	O
defect	O
space	O
within	O
the	O
TA	O
muscle	O
defect	O
site	O
,	O
the	O
GFP	B-GP
+	O
C2C12	O
cells	O
were	O
fluorescently	O
labeled	O
before	O
implantation	O
,	O
and	O
the	O
localized	O
cells	O
were	O
tracked	O
by	O
a	O
double	O
fluorescent	O
imaging	O
based	O
on	O
GFP	B-GP
expression	O
and	O
fluorescent	O
labeling	O
.	O

Progressively	O
-	O
injected	O
C2C12	O
cells	O
showed	O
distinguishable	O
localization	O
within	O
the	O
TA	O
defect	O
site	O
(	O
Fig	O
.	O
5a	O
)	O
where	O
the	O
cells	O
were	O
fluorescently	O
labeled	O
only	O
for	O
1st	O
and	O
4th	O
injection	O
.	O

In	O
the	O
double	O
GFP	B-GP
+	O
fluorescent	O
labeling	O
imaging	O
,	O
fluorescently	O
labeled	O
C2C12	O
cells	O
at	O
1st	O
and	O
4th	O
injection	O
site	O
were	O
clearly	O
visualized	O
as	O
red	O
fluorescence	O
(	O
yellow	O
arrows	O
along	O
with	O
dotted	O
lines	O
in	O
whole	O
TA	O
)	O
while	O
cells	O
injected	O
during	O
the	O
2	O
–	O
3rd	O
injection	O
were	O
stained	O
with	O
GFP	B-GP
without	O
red	O
fluorescent	O
labeling	O
.	O

Single	O
injection	O
of	O
C2C12	O
cells	O
,	O
which	O
represents	O
the	O
same	O
cell	O
number	O
as	O
the	O
total	O
cell	O
number	O
delivered	O
by	O
progressive	O
injections	O
,	O
also	O
showed	O
a	O
few	O
fluorescent	O
signals	O
in	O
the	O
outer	O
part	O
of	O
the	O
TA	O
muscle	O
.	O

In	O
magnified	O
images	O
,	O
the	O
number	O
of	O
injected	O
cells	O
with	O
fluorescently	O
labeled	O
GFP	B-GP
+	O
MHC	B-GP
+	O
C2C12	O
cells	O
(	O
white	O
arrows	O
)	O
is	O
higher	O
with	O
progressive	O
injections	O
than	O
that	O
by	O
single	O
injection	O
(	O
Inner	O
TA	O
).	O

In	O
the	O
inner	O
part	O
of	O
the	O
TA	O
muscle	O
(	O
Fig	O
.	O
5a	O
),	O
the	O
majority	O
of	O
infused	O
C2C12	O
cells	O
by	O
progressive	O
injection	O
formed	O
muscle	O
fibers	O
(	O
MHC	B-GP
+	O
staining	O
)	O
and	O
newly	O
formed	O
muscle	O
fibers	O
(	O
chimeric	O
)	O
(	O
MHC	B-GP
+	O
GFP	B-GP
+	O
labeling	O
,	O
as	O
indicated	O
by	O
white	O
arrows	O
)	O
organized	O
with	O
the	O
host	O
muscle	O
tissue	O
.	O

The	O
outer	O
site	O
of	O
the	O
TA	O
muscle	O
showed	O
different	O
cell	O
localization	O
compared	O
with	O
the	O
inner	O
site	O
.	O

In	O
the	O
progressive	O
group	O
,	O
a	O
number	O
of	O
injected	O
C2C12	O
cells	O
with	O
fluorescent	O
labeling	O
are	O
found	O
to	O
contribute	O
to	O
the	O
muscle	O
formation	O
with	O
host	O
muscle	O
tissues	O
(	O
white	O
arrows	O
).	O

More	O
interestingly	O
,	O
the	O
number	O
of	O
GFP	B-GP
+	O
MHC	B-GP
+	O
fluorescent	O
-	O
labeling	O
positive	O
cells	O
is	O
higher	O
in	O
the	O
progressive	O
injection	O
group	O
than	O
in	O
the	O
single	O
injection	O
group	O
.	O

In	O
addition	O
,	O
a	O
few	O
fluorescently	O
labeled	O
-	O
GFP	B-GP
+	O
C2C12	O
cells	O
at	O
the	O
surface	O
site	O
of	O
the	O
TA	O
muscle	O
are	O
not	O
involved	O
in	O
the	O
muscle	O
formation	O
as	O
indicated	O
by	O
white	O
arrowheads	O
.	O

hMPC	O
injection	O
also	O
showed	O
a	O
similar	O
pattern	O
of	O
cell	O
distribution	O
with	O
C2C12	O
cells	O
(	O
Fig	O
.	O
5b	O
).	O

Progressive	O
injection	O
of	O
hMPCs	O
resulted	O
in	O
efficient	O
distribution	O
at	O
the	O
entire	O
site	O
of	O
the	O
TA	O
muscle	O
,	O
as	O
confirmed	O
by	O
double	O
staining	O
of	O
MHC	B-GP
and	O
human	B-GP
leukocyte	I-GP
antigen	I-GP
(	O
HLA	B-GP
)	O
staining	O
(	O
Fig	O
.	O
5b	O
,	O
lower	O
row	O
).	O

More	O
HLA	B-GP
+	O
MHC	B-GP
+	O
chimeric	O
muscle	O
fibers	O
are	O
clearly	O
found	O
in	O
both	O
inner	O
and	O
outer	O
TA	O
site	O
(	O
white	O
arrows	O
)	O
by	O
progressive	O
injection	O
but	O
not	O
with	O
single	O
injection	O
.	O

Interestingly	O
,	O
some	O
of	O
chimeric	O
muscle	O
fibers	O
(	O
white	O
arrows	O
)	O
in	O
the	O
progressive	O
group	O
in	O
the	O
outer	O
area	O
of	O
the	O
TA	O
muscle	O
tissue	O
are	O
notable	O
in	O
terms	O
of	O
clear	O
involvement	O
of	O
the	O
injected	O
hMPCs	O
(	O
white	O
arrows	O
in	O
outer	O
TA	O
).	O

Differentiation	O
of	O
injected	O
C2C12	O
cells	O
and	O
hMPCs	O
into	O
myofibers	O
or	O
myotubes	O
was	O
quantified	O
by	O
calculating	O
the	O
percentage	O
of	O
fluorescent	O
-	O
labeled	O
-	O
Myogenin	B-GP
+	O
C2C12	O
cells	O
and	O
Myogenin	B-GP
+	O
human	B-GP
nuclear	I-GP
antigen	I-GP
(	O
HNA	B-GP
)+	O
cells	O
in	O
the	O
C2C12	O
-	O
injected	O
group	O
and	O
hMPCs	O
-	O
injected	O
TA	O
muscles	O
,	O
respectively	O
(	O
n	O
=	O
3	O
–	O
4	O
,	O
3	O
–	O
5	O
fields	O
per	O
sample	O
).	O

In	O
both	O
C2C12	O
-	O
injected	O
group	O
and	O
hMPCs	O
-	O
injected	O
TA	O
muscle	O
,	O
the	O
percentage	O
of	O
fluorescently	O
labeled	O
Myogenin	B-GP
+	O
cells	O
and	O
Myogenin	B-GP
+	O
HNA	B-GP
+	O
cells	O
was	O
higher	O
with	O
progressive	O
injections	O
than	O
that	O
by	O
single	O
injection	O
with	O
a	O
statistical	O
difference	O
(	O
Student	O
’	O
s	O
t	O
-	O
test	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
(	O
42	O
.	O
74	O
%	O
±	O
10	O
.	O
63	O
%	O
and	O
19	O
.	O
18	O
%	O
±	O
6	O
.	O
04	O
%	O
in	O
progressive	O
C2C12	O
and	O
hMPCs	O
injection	O
,	O
respectively	O
)	O
(	O
see	O
Supplementary	O
Figs	O
S6	O
and	O
S7	O
).	O

Notably	O
,	O
it	O
was	O
clearly	O
seen	O
that	O
fluorescently	O
labeled	O
C2C12	O
cells	O
were	O
fused	O
to	O
form	O
muscle	O
fibers	O
with	O
host	O
muscle	O
tissues	O
,	O
some	O
of	O
which	O
was	O
Myogenin	B-GP
+	O
cells	O
.	O

Proliferation	O
of	O
injected	O
cells	O
in	O
the	O
TA	O
muscles	O
was	O
evaluated	O
by	O
fluorescent	O
staining	O
images	O
of	O
proliferating	B-GP
cell	I-GP
nuclear	I-GP
antigen	I-GP
(	O
PCNA	B-GP
).	O

The	O
percentage	O
of	O
proliferating	O
C2C12	O
cells	O
(	O
fluorescent	O
labeled	O
PCNA	B-GP
+)	O
and	O
hMPCs	O
(	O
PCNA	B-GP
+	O
HNA	B-GP
+	O
cells	O
)	O
in	O
the	O
progressive	O
injection	O
group	O
was	O
33	O
.	O
31	O
%	O
±	O
15	O
.	O
56	O
%	O
and	O
31	O
.	O
99	O
%	O
±	O
15	O
.	O
84	O
%,	O
respectively	O
,	O
which	O
is	O
higher	O
than	O
in	O
the	O
single	O
injection	O
group	O
(	O
n	O
=	O
3	O
–	O
4	O
,	O
3	O
–	O
5	O
fields	O
per	O
each	O
sample	O
,	O
Student	O
’	O
s	O
t	O
-	O
test	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
(	O
see	O
Supplementary	O
Figs	O
S6	O
and	O
S7	O
).	O

To	O
examine	O
the	O
vascularization	O
and	O
neuronal	O
ingrowth	O
by	O
the	O
injected	O
hMPCs	O
,	O
vWF	B-GP
/	O
α	B-GP
-	I-GP
SMA	I-GP
and	O
NF	B-GP
/	O
AChR	B-GP
/	O
MHC	B-GP
immunostaining	O
were	O
performed	O
,	O
and	O
double	O
-	O
and	O
triple	O
-	O
positive	O
staining	O
was	O
visualized	O
,	O
respectively	O
.	O

Quantitative	O
results	O
of	O
vascularization	O
indicated	O
that	O
only	O
progressive	O
hMPCs	O
injections	O
showed	O
increased	O
vascularization	O
,	O
in	O
terms	O
of	O
number	O
and	O
area	O
of	O
vWF	B-GP
+	O
vessels	O
(/	O
field	O
)	O
(	O
n	O
=	O
3	O
–	O
4	O
,	O
6	O
–	O
10	O
fields	O
per	O
sample	O
,	O
ANOVA	O
and	O
Tukey	O
test	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
(	O
Fig	O
.	O
6b	O
,	O
c	O
),	O
while	O
the	O
degree	O
of	O
vascularization	O
was	O
not	O
statistically	O
different	O
among	O
the	O
no	O
treatment	O
,	O
gel	O
only	O
and	O
single	O
hMPCs	O
injection	O
groups	O
(	O
ANOVA	O
and	O
Tukey	O
test	O
,	O
P	O
>	O
0	O
.	O
05	O
).	O

Meanwhile	O
,	O
the	O
degree	O
of	O
vascularization	O
between	O
inner	O
region	O
and	O
outer	O
region	O
in	O
each	O
group	O
was	O
not	O
statistically	O
different	O
in	O
terms	O
of	O
the	O
number	O
and	O
area	O
of	O
vWF	B-GP
+	O
vessels	O
(/	O
field	O
),	O
maturation	O
index	O
(%)	O
and	O
percentage	O
of	O
different	O
vessel	O
sizes	O
(	O
data	O
not	O
shown	O
,	O
Student	O
’	O
s	O
t	O
-	O
test	O
,	O
P	O
>	O
0	O
.	O
05	O
).	O

Neuronal	O
ingrowth	O
of	O
the	O
TA	O
muscle	O
was	O
confirmed	O
as	O
NF	B-GP
+/	O
AChR	B-GP
+/	O
MHC	B-GP
+	O
staining	O
in	O
both	O
progressive	O
and	O
single	O
injection	O
,	O
and	O
the	O
level	O
of	O
neuronal	O
ingrowth	O
was	O
not	O
significantly	O
different	O
between	O
the	O
injection	O
methods	O
(	O
see	O
Supplementary	O
Fig	O
.	O

S8	O
).	O

Discussion	O

With	O
increasing	O
interests	O
in	O
translation	O
of	O
cell	O
-	O
based	O
therapies	O
from	O
pre	O
-	O
clinical	O
to	O
clinical	O
applications	O
,	O
appropriate	O
treatment	O
of	O
large	O
volumetric	O
tissue	O
defects	O
relies	O
on	O
efficient	O
cell	O
survival	O
following	O
implantation1530	O
.	O

While	O
several	O
cell	O
-	O
based	O
approaches	O
using	O
TE	O
and	O
RM	O
techniques	O
have	O
facilitated	O
successful	O
outcomes	O
in	O
terms	O
of	O
recovery	O
of	O
avascular	O
tissue	O
function	O
through	O
an	O
effective	O
tissue	O
regeneration	O
conditions234	O
,	O
reconstruction	O
of	O
volumetric	O
and	O
highly	O
-	O
vascularized	O
tissues	O
or	O
organs	O
on	O
a	O
large	O
scale	O
(>	O
mm	O
to	O
cm	O
)	O
in	O
vivo	O
remains	O
challenging	O
.	O

Decreased	O
cell	O
survival	O
of	O
the	O
implanted	O
cells	O
due	O
to	O
an	O
insufficient	O
blood	O
supply	O
to	O
the	O
implanted	O
cells	O
has	O
limited	O
the	O
efficient	O
integration	O
of	O
such	O
large	O
constructs	O
with	O
the	O
host	O
vascularization11516	O
.	O

To	O
address	O
this	O
issue	O
,	O
several	O
pre	O
-	O
vascularization	O
approaches	O
have	O
been	O
developed	O
and	O
many	O
have	O
demonstrated	O
successful	O
reconstruction	O
of	O
vascularized	O
tissues	O
in	O
in	O
vitro	O
and	O
in	O
vivo1531	O
.	O

The	O
time	O
-	O
consuming	O
vascularization	O
process	O
,	O
however	O
,	O
must	O
be	O
overcome	O
to	O
allow	O
for	O
the	O
volumetric	O
repair1530	O
.	O

Currently	O
,	O
efficient	O
method	O
is	O
available	O
to	O
treat	O
the	O
volumetric	O
tissue	O
defect	O
;	O
therefore	O
,	O
we	O
developed	O
an	O
effective	O
cell	O
delivery	O
method	O
to	O
construct	O
a	O
large	O
size	O
muscle	O
tissue	O
through	O
an	O
efficient	O
vascularization	O
process	O
in	O
vivo	O
.	O
Our	O
results	O
from	O
histological	O
and	O
immunohistochemical	O
analysis	O
demonstrate	O
that	O
muscle	O
cell	O
delivery	O
by	O
multiple	O
cell	O
injection	O
in	O
a	O
progressive	O
manner	O
facilitated	O
large	O
scale	O
muscle	O
(>	O
mm	O
)	O
tissue	O
formation	O
in	O
an	O
ectopic	O
mouse	B-OG
model	O
,	O
and	O
the	O
reconstructed	O
tissue	O
is	O
well	O
-	O
integrated	O
with	O
the	O
host	O
vascular	O
system	O
and	O
neuronal	O
ingrowth	O
.	O

When	O
this	O
technique	O
was	O
applied	O
to	O
a	O
skeletal	B-DS
muscle	I-DS
injury	I-DS
model	O
with	O
a	O
critical	O
volumetric	O
defect	O
,	O
the	O
progressive	O
cell	O
injection	O
demonstrated	O
enhanced	O
muscle	O
tissue	O
reconstruction	O
and	O
improved	O
functional	O
recovery	O
when	O
compared	O
with	O
single	O
injection	O
.	O

From	O
these	O
results	O
,	O
we	O
suggest	O
that	O
our	O
cell	O
delivery	O
system	O
in	O
a	O
multiple	O
progressive	O
manner	O
is	O
a	O
promising	O
and	O
effective	O
method	O
to	O
reconstruct	O
volumetric	O
muscle	O
and	O
thereby	O
improve	O
muscle	O
function	O
in	O
vivo	O
.	O

The	O
idea	O
of	O
‘	O
multiple	O
and	O
progressive	O
cell	O
delivery	O
’	O
for	O
volumetric	O
tissue	O
reconstruction	O
arose	O
from	O
the	O
phenomena	O
frequently	O
observed	O
in	O
cell	O
-	O
based	O
approaches	O
;	O
32	O
which	O
includes	O
decreased	O
cell	O
survival	O
of	O
transplanted	O
cells	O
or	O
implantation	O
of	O
engineered	O
tissue	O
construct	O
due	O
to	O
the	O
insufficient	O
delivery	O
of	O
oxygen	O
and	O
nutrients	O
as	O
a	O
result	O
of	O
the	O
time	O
-	O
consuming	O
process	O
of	O
vascularization	O
.	O

Large	O
defect	O
sizes	O
(	O
e	O
.	O
g	O
.	O
mm	O
-	O
cm	O
in	O
size	O
)	O
are	O
particularly	O
affected	O
by	O
decreased	O
cell	O
viability	O
when	O
in	O
the	O
vascularized	O
tissues	O
needs	O
to	O
be	O
repaired	O
.	O

In	O
this	O
case	O
,	O
a	O
high	O
number	O
of	O
cells	O
are	O
usually	O
required	O
for	O
treatment	O
,	O
and	O
the	O
requirement	O
for	O
oxygen	O
and	O
nutrients	O
increases	O
with	O
the	O
increased	O
cell	O
number1	O
.	O

To	O
address	O
this	O
critical	O
issue	O
,	O
we	O
hypothesized	O
that	O
a	O
multiple	O
number	O
of	O
cell	O
injections	O
performed	O
in	O
a	O
progressive	O
manner	O
would	O
effectively	O
enhance	O
volumetric	O
tissue	O
in	O
vivo	O
(	O
Fig	O
.	O
1	O
).	O

This	O
delivery	O
method	O
is	O
primarily	O
designed	O
to	O
improve	O
the	O
viability	O
of	O
the	O
delivered	O
cells	O
at	O
each	O
injection	O
to	O
allow	O
for	O
efficient	O
vascularization	O
surrounding	O
the	O
cells	O
at	O
the	O
delivery	O
site	O
.	O

The	O
first	O
injection	O
of	O
cells	O
at	O
an	O
appropriate	O
cell	O
number	O
and	O
injection	O
volume	O
will	O
obtain	O
sufficient	O
oxygen	O
from	O
the	O
host	O
vessels	O
at	O
the	O
injection	O
site	O
.	O

Following	O
the	O
first	O
injection	O
,	O
the	O
host	O
vasculature	O
will	O
surround	O
the	O
site	O
of	O
the	O
injection	O
within	O
a	O
few	O
days	O
and	O
provide	O
vascular	O
beds	O
for	O
subsequent	O
cell	O
injections	O
.	O

The	O
period	O
of	O
vascularization	O
following	O
each	O
subsequent	O
injection	O
results	O
in	O
the	O
formation	O
of	O
a	O
suitable	O
angiogenic	O
environment	O
for	O
the	O
injected	O
cells	O
.	O

Repeating	O
the	O
cell	O
injection	O
process	O
allows	O
a	O
larger	O
and	O
thicker	O
tissue	O
with	O
structural	O
and	O
functional	O
properties	O
to	O
be	O
reconstructed	O
in	O
vivo	O
(	O
Fig	O
.	O
1	O
).	O

To	O
test	O
the	O
hypothesis	O
,	O
we	O
utilized	O
an	O
ectopic	O
implantation	O
model	O
through	O
subcutaneous	O
injection	O
in	O
athymic	O
mice	B-OG
.	O

The	O
subcutaneous	O
injection	O
model	O
was	O
chosen	O
for	O
several	O
reasons	O
including	O
a	O
highly	O
vascularized	O
,	O
non	O
-	O
myogenic	O
tissue	O
that	O
was	O
easily	O
accessible	O
for	O
cell	O
injection	O
.	O

It	O
was	O
particularly	O
important	O
to	O
evaluate	O
muscle	O
regeneration	O
within	O
a	O
non	O
-	O
myogenic	O
environment	O
to	O
evaluate	O
whether	O
the	O
volumetric	O
muscle	O
formation	O
in	O
vivo	O
occurred	O
as	O
a	O
result	O
of	O
the	O
injected	O
muscle	O
cells	O
following	O
the	O
progressive	O
cell	O
injection	O
strategy	O
and	O
without	O
any	O
contribution	O
of	O
host	O
muscle	O
tissue	O
.	O

Using	O
this	O
model	O
,	O
we	O
first	O
attempted	O
to	O
optimize	O
cell	O
density	O
for	O
injection	O
.	O

Subcutaneous	O
injection	O
of	O
three	O
different	O
cell	O
concentrations	O
showed	O
dramatically	O
different	O
results	O
in	O
terms	O
of	O
cell	O
survival	O
,	O
where	O
highest	O
cell	O
density	O
(	O
30	O
×	O
106	O
cells	O
per	O
ml	O
)	O
indicated	O
higher	O
necrosis	O
with	O
an	O
exponential	O
increase	O
(	O
see	O
Supplementary	O
Fig	O
.	O

S1	O
),	O
thus	O
,	O
indicating	O
that	O
a	O
higher	O
cell	O
density	O
within	O
the	O
implanted	O
area	O
exceeded	O
the	O
amount	O
of	O
oxygen	O
and	O
nutrients	O
that	O
could	O
be	O
supplied	O
by	O
the	O
host	O
.	O

It	O
is	O
plausible	O
that	O
high	O
cell	O
concentration	O
increased	O
oxygen	O
consumption	O
by	O
cells	O
,	O
while	O
diffusion	O
of	O
oxygen	O
decreased	O
in	O
denser	O
tissues	O
.	O

Therefore	O
,	O
cell	O
concentration	O
of	O
10	O
×	O
106	O
cells	O
per	O
ml	O
was	O
selected	O
for	O
this	O
study	O
to	O
prevent	O
necrosis	O
and	O
improve	O
tissue	O
formation	O
.	O

In	O
addition	O
to	O
the	O
selection	O
of	O
an	O
appropriate	O
cell	O
density	O
for	O
the	O
cell	O
injection	O
,	O
the	O
time	O
interval	O
between	O
each	O
cell	O
injection	O
was	O
an	O
important	O
parameter	O
to	O
be	O
considered	O
.	O

As	O
a	O
proof	O
-	O
of	O
-	O
concept	O
study	O
,	O
we	O
chose	O
an	O
interval	O
of	O
one	O
week	O
between	O
each	O
of	O
the	O
multiple	O
cell	O
injections	O
based	O
on	O
the	O
time	O
for	O
normal	O
vascularization	O
to	O
occur	O
in	O
the	O
body29	O
.	O

Generally	O
,	O
the	O
new	O
vascularization	O
surrounding	O
the	O
cell	O
injection	O
site	O
will	O
occur	O
within	O
one	O
week	O
and	O
new	O
blood	O
vessel	O
formation	O
under	O
maturation	O
will	O
occur	O
at	O
2	O
–	O
3	O
weeks	O
.	O

We	O
attempted	O
to	O
perform	O
four	O
series	O
of	O
cell	O
injections	O
in	O
a	O
progressive	O
manner	O
in	O
the	O
ectopic	O
implantation	O
study	O
(	O
Fig	O
.	O
3	O
);	O
therefore	O
,	O
we	O
expected	O
that	O
the	O
1st	O
–	O
3rd	O
injection	O
,	O
which	O
occurred	O
at	O
least	O
two	O
weeks	O
before	O
harvesting	O
the	O
reconstruct	O
tissue	O
formation	O
,	O
would	O
form	O
the	O
appropriate	O
vascular	O
maturation	O
while	O
the	O
4th	O
(	O
final	O
)	O
injection	O
site	O
would	O
show	O
newly	O
formed	O
capillaries	O
.	O

The	O
results	O
of	O
immunostaining	O
and	O
quantification	O
analysis	O
confirm	O
that	O
one	O
week	O
between	O
each	O
injection	O
established	O
an	O
appropriate	O
time	O
interval	O
to	O
produce	O
efficient	O
vascularization	O
along	O
each	O
cell	O
injection	O
(	O
Fig	O
.	O
3b	O
,	O
d	O
).	O

Our	O
results	O
are	O
consistent	O
with	O
the	O
outcomes	O
from	O
another	O
study	O
that	O
established	O
a	O
vascular	O
chamber	O
in	O
vivo	O
using	O
an	O
arterio	O
-	O
venous	O
loop	O
(	O
AV	O
loop	O
)	O
and	O
optimized	O
the	O
timing	O
of	O
cell	O
implantation	O
to	O
determine	O
efficient	O
cell	O
survival33	O
.	O

Their	O
results	O
showed	O
that	O
angiogenic	O
activity	O
peaked	O
between	O
7	O
–	O
10	O
days	O
after	O
insertion	O
of	O
the	O
AV	O
loop	O
and	O
suggested	O
that	O
as	O
further	O
vascularization	O
led	O
to	O
an	O
increased	O
survival	O
among	O
the	O
implanted	O
cells	O
.	O

This	O
study	O
revealed	O
that	O
delayed	O
cell	O
implantation	O
(	O
at	O
day	O
7	O
)	O
into	O
a	O
site	O
with	O
well	O
-	O
established	O
vessels	O
could	O
improve	O
cell	O
survival33	O
.	O

Another	O
parameter	O
for	O
successful	O
cell	O
injection	O
strategy	O
involves	O
an	O
accurately	O
controlled	O
injection	O
volume	O
to	O
reduce	O
cell	O
necrosis	O
after	O
cell	O
transplantation	O
.	O

Generally	O
,	O
the	O
implanted	O
cells	O
can	O
obtain	O
an	O
adequate	O
oxygen	O
and	O
nutrient	O
supply	O
within	O
200	O
μm	O
from	O
adjacent	O
vasculatures	O
as	O
well	O
as	O
through	O
diffusion	O
at	O
a	O
distance	O
of	O
0	O
.	O
2	O
–	O
0	O
.	O
3	O
cm134	O
.	O

While	O
cell	O
density	O
was	O
optimized	O
at	O
10	O
×	O
106	O
cells	O
per	O
ml	O
for	O
injection	O
(	O
see	O
Supplementary	O
Fig	O
.	O

S1	O
),	O
the	O
higher	O
cell	O
injection	O
volume	O
in	O
the	O
single	O
injection	O
resulted	O
in	O
significantly	O
lower	O
cell	O
survival	O
compared	O
to	O
progressive	O
injection	O
(	O
Fig	O
.	O
2c	O
).	O

Thus	O
,	O
injection	O
volume	O
can	O
affect	O
cell	O
survival	O
.	O

Since	O
the	O
volume	O
of	O
1	O
.	O
2	O
ml	O
for	O
the	O
single	O
injection	O
can	O
prepare	O
1	O
.	O
2	O
cm3	O
in	O
dimension	O
(>	O
1	O
×	O
1	O
×	O
1	O
cm	O
),	O
the	O
cells	O
localized	O
to	O
the	O
center	O
of	O
the	O
fibrin	B-GP
gel	O
will	O
encounter	O
a	O
hypoxic	O
condition	O
with	O
limited	O
oxygen	O
diffusion	O
from	O
the	O
host	O
vessels1151620	O
,	O
and	O
the	O
result	O
will	O
be	O
increased	O
cell	O
necrosis	O
.	O

Eventually	O
,	O
the	O
increased	O
cell	O
death	O
will	O
lead	O
to	O
the	O
failure	O
of	O
the	O
volumetric	O
tissue	O
construction	O
(	O
Fig	O
.	O
2c	O
,	O
single	O
injection	O
).	O

Meanwhile	O
,	O
the	O
volume	O
of	O
each	O
injection	O
in	O
the	O
progressive	O
injection	O
model	O
was	O
0	O
.	O
3	O
ml	O
and	O
is	O
equivalent	O
to	O
0	O
.	O
3	O
cm3	O
,	O
which	O
can	O
reconstruct	O
an	O
implant	O
of	O
approximately	O
300	O
mm3	O
in	O
volume	O
due	O
to	O
the	O
diffusion	O
of	O
oxygen	O
from	O
the	O
surrounding	O
blood	O
vessels	O
.	O

The	O
injected	O
cells	O
obtain	O
an	O
adequate	O
blood	O
supply	O
through	O
diffusion	O
and	O
have	O
greater	O
survival	O
.	O

Therefore	O
,	O
the	O
volume	O
for	O
injection	O
should	O
be	O
controlled	O
to	O
ensure	O
cell	O
survival	O
and	O
subsequent	O
formation	O
of	O
tissue	O
reconstruction	O
within	O
the	O
implant	O
site	O
(	O
Fig	O
.	O
3	O
).	O

Optimization	O
of	O
several	O
parameters	O
such	O
as	O
cell	O
density	O
,	O
time	O
interval	O
between	O
cell	O
injections	O
,	O
and	O
volume	O
for	O
cell	O
injections	O
allowed	O
us	O
to	O
demonstrate	O
the	O
possibility	O
to	O
use	O
a	O
progressive	O
cell	O
injection	O
model	O
to	O
facilitate	O
volumetric	O
muscle	O
tissue	O
construction	O
through	O
efficient	O
vascularization	O
events	O
in	O
an	O
ectopic	O
site	O
(	O
Fig	O
.	O
3	O
).	O

We	O
show	O
that	O
the	O
levels	O
of	O
vascularization	O
in	O
the	O
progressive	O
cell	O
injection	O
group	O
were	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
single	O
injection	O
group	O
in	O
the	O
ectopic	O
implantation	O
study	O
.	O

Notably	O
,	O
the	O
vascular	O
formation	O
pattern	O
in	O
the	O
core	O
region	O
was	O
significantly	O
different	O
.	O

While	O
the	O
progressive	O
cell	O
injections	O
resulted	O
in	O
the	O
formation	O
of	O
larger	O
(>	O
500	O
μm	O
)	O
and	O
mature	O
blood	O
vessels	O
in	O
the	O
core	O
region	O
,	O
the	O
area	O
of	O
blood	O
vessels	O
present	O
in	O
the	O
single	O
injection	O
group	O
was	O
significantly	O
lower	O
by	O
a	O
300	O
-	O
fold	O
difference	O
.	O

Interestingly	O
,	O
the	O
majority	O
of	O
the	O
blood	O
vessels	O
(	O
90	O
%)	O
found	O
in	O
the	O
single	O
cell	O
injection	O
group	O
consisted	O
of	O
small	O
size	O
capillaries	O
(<	O
200	O
μm	O
)	O
(	O
Fig	O
.	O
3	O
and	O
Supplementary	O
Fig	O
.	O

S3	O
).	O

As	O
such	O
,	O
it	O
is	O
speculated	O
that	O
the	O
progressive	O
cell	O
injection	O
strategy	O
facilitates	O
the	O
formation	O
of	O
volumetric	O
viable	O
tissue	O
by	O
establishing	O
vascular	O
networks	O
throughout	O
the	O
tissue	O
construct	O
,	O
even	O
in	O
the	O
core	O
region	O
,	O
thus	O
overcoming	O
the	O
problems	O
resulting	O
from	O
the	O
conventional	O
single	O
cell	O
injection	O
method	O
,	O
such	O
as	O
necrotic	O
tissue	O
core	O
due	O
to	O
diffusion	O
limitation	O
.	O

Encouraged	O
by	O
the	O
promising	O
outcomes	O
,	O
this	O
novel	O
cell	O
delivery	O
system	O
was	O
applied	O
to	O
treat	O
a	O
critical	O
-	O
sized	O
muscle	O
tissue	O
defect	O
.	O

As	O
the	O
first	O
target	O
for	O
reconstruction	O
of	O
damaged	O
tissues	O
or	O
organs	O
,	O
the	O
strategy	O
of	O
progressive	O
cell	O
injections	O
was	O
applied	O
to	O
skeletal	B-DS
muscle	I-DS
tissue	I-DS
injuries	I-DS
,	O
particularly	O
VML	O
,	O
which	O
is	O
caused	O
by	O
traumatic	O
or	O
surgical	O
loss	O
.	O

VML	O
is	O
a	O
challenging	O
clinical	O
problem	O
for	O
military	O
,	O
civilian	O
,	O
and	O
sports	O
medicine	O
since	O
skeletal	O
muscle	O
is	O
a	O
relatively	O
large	O
,	O
thick	O
tissue	O
that	O
often	O
involves	O
other	O
tissue	O
or	O
organ	O
damage	O
such	O
as	O
skin	O
,	O
bone	O
,	O
and	O
internal	O
organs35	O
.	O

As	O
an	O
animal	B-OG
model	O
for	O
VML	O
,	O
we	O
utilized	O
a	O
rat	B-OG
TA	O
muscle	O
defect	O
model	O
that	O
was	O
developed	O
by	O
Wu	O
,	O
X	O
.	O
et	O
al36	O
.	O
after	O
modification	O
.	O

This	O
is	O
a	O
standardized	O
rodent	O
model	O
of	O
VML	O
injury	B-DS
generated	O
by	O
excising	O
~	O
20	O
%	O
of	O
the	O
middle	O
of	O
the	O
TA	O
muscle	O
,	O
and	O
muscle	O
weight	O
and	O
tetanic	O
muscle	O
force	O
are	O
not	O
recovered	O
until	O
6	O
months3637	O
.	O

In	O
this	O
study	O
,	O
we	O
introduced	O
a	O
larger	O
defect	O
size	O
(~	O
30	O
%	O
excision	O
of	O
TA	O
muscles	O
)	O
to	O
produce	O
a	O
critical	O
sized	O
muscle	O
defect	O
animal	B-OG
model	O
.	O

The	O
anatomical	O
and	O
functional	O
analysis	O
demonstrated	O
that	O
our	O
progressive	O
cell	O
injection	O
model	O
could	O
significantly	O
increase	O
muscle	O
mass	O
and	O
thickness	O
,	O
reduce	O
fibrosis	O
and	O
partial	O
restoration	O
of	O
muscle	O
function	O
in	O
the	O
TA	O
defect	O
when	O
compared	O
to	O
that	O
of	O
a	O
single	O
injection	O
(	O
Fig	O
.	O
4	O
);	O
moreover	O
,	O
recovery	O
was	O
confirmed	O
by	O
myotubes	O
or	O
myofibers	O
formation	O
by	O
progressively	O
injected	O
cells	O
(	O
Fig	O
.	O
5	O
and	O
Supplementary	O
Figs	O
S6	O
and	O
S7	O
)	O
as	O
well	O
as	O
vascularization	O
(	O
Fig	O
.	O
6	O
)	O
and	O
neuronal	O
ingrowth	O
(	O
see	O
Supplementary	O
Fig	O
.	O

S8	O
).	O

Multiple	O
cell	O
injections	O
in	O
a	O
progressive	O
manner	O
showed	O
better	O
cell	O
engraftment	O
over	O
the	O
single	O
injection	O
method	O
,	O
as	O
evidenced	O
by	O
the	O
presence	O
of	O
numerous	O
GFP	B-GP
+	O
or	O
DiI	O
+	O
cells	O
and	O
HLA	B-GP
+	O
or	O
HNA	B-GP
+	O
cells	O
in	O
the	O
progressive	O
cell	O
injection	O
group	O
,	O
as	O
compared	O
with	O
those	O
in	O
the	O
single	O
cell	O
injection	O
group	O
.	O

In	O
addition	O
,	O
higher	O
proliferation	O
of	O
the	O
engrafted	O
cells	O
(	O
30	O
%	O
of	O
engrafted	O
hMPCs	O
)	O
was	O
observed	O
in	O
the	O
progressive	O
injection	O
group	O
than	O
in	O
the	O
single	O
cell	O
injection	O
group	O
.	O

Based	O
on	O
these	O
observations	O
,	O
it	O
is	O
speculated	O
that	O
if	O
the	O
same	O
number	O
of	O
cells	O
are	O
injected	O
,	O
the	O
strategy	O
of	O
progressive	O
cell	O
injections	O
would	O
increase	O
cell	O
engraftment	O
and	O
proliferation	O
,	O
as	O
compared	O
to	O
the	O
single	O
injection	O
method	O
.	O

Moreover	O
,	O
the	O
myogenic	O
capacity	O
of	O
engrafted	O
cells	O
would	O
be	O
increased	O
by	O
the	O
progressive	O
injection	O
strategy	O
.	O

The	O
percentage	O
of	O
differentiating	O
cells	O
in	O
the	O
progressive	O
-	O
C2C12	O
and	O
hMPCs	O
injection	O
was	O
43	O
.	O
74	O
%	O
and	O
19	O
.	O
18	O
%,	O
respectively	O
,	O
at	O
1	O
week	O
after	O
the	O
final	O
injection	O
.	O

While	O
the	O
current	O
study	O
showed	O
the	O
significant	O
potential	O
of	O
the	O
progressive	O
cell	O
injection	O
strategy	O
,	O
several	O
limitations	O
remain	O
to	O
be	O
solved	O
before	O
the	O
application	O
could	O
be	O
translated	O
.	O

Since	O
volumetric	O
tissue	O
repair	O
and	O
functional	O
recovery	O
was	O
evaluated	O
only	O
up	O
to	O
4	O
weeks	O
in	O
a	O
VML	O
injury	B-DS
model	O
,	O
reliability	O
of	O
the	O
therapeutic	O
effects	O
need	O
to	O
be	O
demonstrated	O
over	O
a	O
long	O
-	O
term	O
.	O

In	O
terms	O
of	O
defect	O
size	O
,	O
in	O
this	O
study	O
,	O
we	O
used	O
a	O
TA	O
injury	B-DS
model	O
of	O
approximately	O
30	O
%	O
muscle	O
mass	O
defect	O
.	O

Although	O
the	O
extent	O
of	O
defect	O
is	O
significant	O
in	O
a	O
rodent	O
model	O
,	O
it	O
is	O
unclear	O
whether	O
this	O
defect	O
size	O
reflects	O
the	O
clinical	O
conditions	O
presented	O
in	O
humans	B-OG
.	O

Further	O
investigations	O
using	O
a	O
larger	O
animal	B-OG
model	O
with	O
critical	O
defect	O
size	O
and	O
mass38	O
should	O
be	O
performed	O
to	O
determine	O
the	O
effectiveness	O
of	O
the	O
progressive	O
cell	O
injections	O
strategy	O
.	O

Muscle	O
function	O
is	O
closely	O
related	O
to	O
innervation	O
and	O
anti	O
-	O
fibrosis	O
;	O
therefore	O
,	O
specific	O
factors	O
that	O
facilitate	O
efficient	O
innervation	O
and	O
reduction	O
in	O
fibrosis	O
should	O
be	O
considered	O
to	O
improve	O
muscle	O
function	O
.	O

Such	O
factors	O
include	O
agrin39	B-GP
or	O
suramin40	O
to	O
accelerate	O
innervation	O
or	O
reduce	O
fibrosis	O
,	O
respectively	O
.	O

This	O
manuscript	O
describes	O
a	O
proof	O
-	O
of	O
-	O
concept	O
study	O
showing	O
that	O
multiple	O
cell	O
injections	O
result	O
in	O
enhanced	O
cell	O
survival	O
than	O
single	O
injection	O
,	O
which	O
contributes	O
to	O
improved	O
muscle	O
function	O
structurally	O
and	O
physically	O
.	O

To	O
prove	O
the	O
hypothesis	O
,	O
we	O
developed	O
a	O
multiple	O
injection	O
protocol	O
that	O
is	O
performed	O
in	O
a	O
progressive	O
manner	O
with	O
several	O
cell	O
injection	O
parameters	O
.	O

Although	O
we	O
have	O
obtained	O
positive	O
outcomes	O
,	O
in	O
terms	O
of	O
muscle	O
recovery	O
using	O
a	O
pre	O
-	O
clinical	O
animal	B-OG
model	O
,	O
translation	O
of	O
this	O
technology	O
into	O
the	O
clinical	O
settings	O
requires	O
further	O
optimization	O
and	O
refinement	O
,	O
as	O
well	O
as	O
validation	O
in	O
a	O
clinically	O
relevant	O
animal	B-OG
model	O
.	O

For	O
example	O
,	O
translation	O
of	O
this	O
technique	O
to	O
clinical	O
applications	O
needs	O
modification	O
of	O
the	O
cell	O
injection	O
parameters	O
,	O
depending	O
on	O
the	O
target	O
tissue	O
and	O
defect	O
size	O
including	O
injection	O
volume	O
,	O
injection	O
time	O
interval	O
and	O
cell	O
concentration	O
.	O

Selection	O
of	O
a	O
cell	O
delivery	O
vehicle	O
should	O
also	O
be	O
considered	O
for	O
clinical	O
translation	O
.	O

In	O
this	O
study	O
,	O
fibrin	B-GP
gel	O
was	O
used	O
as	O
a	O
cell	O
delivery	O
vehicle	O
since	O
it	O
has	O
been	O
widely	O
used	O
in	O
various	O
clinical	O
applications	O
.	O

Since	O
a	O
hydrogel	O
system	O
such	O
as	O
fibrin	B-GP
gel	O
usually	O
displays	O
weakness	O
in	O
mechanical	O
property	O
,	O
other	O
biocompatible	O
materials	O
with	O
enhanced	O
mechanical	O
strength	O
should	O
be	O
identified	O
in	O
order	O
to	O
maintain	O
the	O
implant	O
volume	O
for	O
a	O
longer	O
period	O
of	O
time	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
provides	O
a	O
novel	O
cell	O
delivery	O
strategy	O
utilizing	O
an	O
appropriate	O
and	O
efficient	O
in	O
vivo	O
vascularization	O
process	O
to	O
overcome	O
the	O
reduced	O
cell	O
survival	O
limitation	O
of	O
current	O
cell	O
-	O
based	O
therapies	O
.	O

The	O
concept	O
of	O
“	O
multiple	O
and	O
progressive	O
cell	O
injections	O
”	O
was	O
supported	O
by	O
demonstrating	O
that	O
the	O
progressive	O
cell	O
injections	O
resulted	O
in	O
an	O
improved	O
cell	O
survival	O
through	O
normal	O
and	O
efficient	O
angiogeneic	O
events	O
surrounding	O
the	O
implant	O
and	O
led	O
to	O
reconstruction	O
of	O
volumetric	O
muscle	O
tissues	O
in	O
vivo	O
.	O

In	O
addition	O
,	O
this	O
novel	O
strategy	O
was	O
applied	O
to	O
a	O
critical	O
-	O
size	O
muscle	O
defect	O
to	O
show	O
restoration	O
of	O
muscle	O
mass	O
and	O
function	O
in	O
a	O
VML	O
animal	B-OG
model	O
.	O

Therefore	O
,	O
multiple	O
cell	O
injections	O
in	O
a	O
progress	O
manner	O
present	O
a	O
promising	O
strategy	O
for	O
volumetric	O
tissue	O
repair	O
in	O
TE	O
and	O
RM	O
.	O

Methods	O

Cell	O
culture	O
and	O
materials	O
preparation	O

C2C12	O
mouse	B-OG
myoblasts	O
(	O
ATCC	O
,	O
Manassas	O
,	O
VA	O
)	O
were	O
transduced	O
with	O
GFP	B-GP
to	O
prepare	O
GFP	B-GP
+	O
-	O
C2C12	O
with	O
a	O
method	O
developed	O
previously41	O
.	O

GFP	B-GP
+	O
-	O
C2C12	O
cells	O
were	O
cultured	O
in	O
DMEM	O
/	O
high	O
glucose	O
(	O
Thermo	O
Scientific	O
Inc	O
.,	O
Waltham	O
,	O
MA	O
)	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
,	O
Gibco	O
,	O
Carlsbad	O
,	O
CA	O
)	O
and	O
1	O
%	O
penicillin	O
/	O
streptomycin	O
(	O
PS	O
,	O
Thermo	O
Scientific	O
)	O
at	O
37	O
°	O
C	O
with	O
5	O
%	O
CO2	O
.	O

During	O
the	O
cell	O
culture	O
,	O
the	O
GFP	B-GP
expression	O
of	O
C2C12	O
cells	O
was	O
confirmed	O
by	O
a	O
fluorescent	O
imaging	O
.	O

As	O
another	O
cell	O
source	O
for	O
this	O
study	O
,	O
hMPCs	O
were	O
used	O
after	O
isolation	O
and	O
expansion	O
.	O

hMPC	O
were	O
isolated	O
from	O
human	B-OG
muscle	O
biopsies	O
as	O
previously	O
described42	O
and	O
expanded	O
in	O
a	O
growth	O
medium	O
composed	O
of	O
DMEM	O
/	O
high	O
glucose	O
,	O
20	O
%	O
FBS	O
,	O
2	O
%	O
chicken	B-OG
embryo	O
extract	O
(	O
Gemini	O
Bio	O
-	O
Products	O
,	O
West	O
Sacramento	O
,	O
CA	O
)	O
and	O
1	O
%	O
PS	O
.	O

Cells	O
were	O
expanded	O
up	O
to	O
passage	O
4	O
for	O
cell	O
injection	O
study	O
.	O

As	O
a	O
vehicle	O
for	O
the	O
cell	O
injection	O
,	O
a	O
fibrin	B-GP
gel	O
system	O
was	O
used	O
.	O

To	O
form	O
the	O
fibrin	B-GP
gel	O
,	O
40	O
mg	O
ml	O
−	O
1	O
of	O
fibrinogen	B-GP
solution	O
and	O
40	O
U	O
ml	O
−	O
1	O
of	O
thrombin	B-GP
solution	O
(	O
Sigma	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
)	O
were	O
prepared	O
by	O
dissolving	O
fibrinogen	B-GP
from	O
bovine	O
plasma	O
(	O
Sigma	O
)	O
in	O
0	O
.	O
9	O
%	O
sodium	O
chloride	O
saline	O
solution	O
,	O
and	O
bovine	O
thrombin	B-GP
(	O
Sigma	O
)	O
in	O
25	O
mM	O
CaCl2	O
in	O
saline	O
solution	O
,	O
respectively	O
.	O

For	O
cell	O
injection	O
,	O
the	O
muscle	O
cells	O
were	O
suspended	O
with	O
fibrinogen	B-GP
solution	O
and	O
adjusted	O
to	O
a	O
cell	O
concentration	O
of	O
20	O
×	O
106	O
cells	O
per	O
ml	O
to	O
yield	O
a	O
final	O
cell	O
concentration	O
of	O
10	O
×	O
106	O
cells	O
per	O
ml	O
in	O
the	O
fibrin	B-GP
gel	O
after	O
mixing	O
with	O
thrombin	B-GP
solution	O
at	O
a	O
1	O
:	O
1	O
ratio	O
.	O

Ectopic	O
cell	O
injection	O

All	O
animal	B-OG
procedures	O
were	O
performed	O
in	O
accordance	O
with	O
a	O
protocol	O
approved	O
by	O
the	O
Institutional	O
Animal	B-OG
Care	O
and	O
Use	O
Committee	O
at	O
Wake	O
Forest	O
University	O
School	O
of	O
Medicine	O
.	O

Male	O
athymic	O
mice	B-OG
(	O
6	O
–	O
8	O
weeks	O
old	O
,	O
total	O
24	O
mice	B-OG
)	O
were	O
obtained	O
from	O
Charles	O
River	O
Laboratory	O
(	O
Wilmington	O
,	O
MA	O
).	O

Anesthesia	O
was	O
induced	O
by	O
using	O
3	O
%	O
isoflurane	O
before	O
surgical	O
procedures	O
.	O

Under	O
aseptic	O
conditions	O
,	O
subcutaneous	O
injections	O
into	O
the	O
dorsal	O
to	O
dorso	O
-	O
lateral	O
region	O
were	O
performed	O
.	O

For	O
progressive	O
cell	O
injections	O
,	O
C2C12	O
cells	O
in	O
a	O
fibrin	B-GP
gel	O
were	O
delivered	O
into	O
the	O
left	O
dorsal	O
regions	O
of	O
mice	B-OG
;	O
2	O
,	O
4	O
,	O
6	O
,	O
and	O
8	O
injections	O
(	O
n	O
=	O
3	O
–	O
4	O
).	O

Injections	O
were	O
performed	O
every	O
7	O
days	O
at	O
the	O
same	O
site	O
where	O
the	O
former	O
injection	O
was	O
done	O
.	O

As	O
control	O
,	O
the	O
same	O
volume	O
of	O
gel	O
without	O
cells	O
was	O
injected	O
into	O
the	O
contralateral	O
region	O
of	O
each	O
animal	B-OG
in	O
the	O
same	O
manner	O
.	O

For	O
each	O
injection	O
,	O
150	O
μl	O
volume	O
of	O
fibrinogen	B-GP
solution	O
with	O
or	O
without	O
cells	O
was	O
injected	O
using	O
a	O
26	O
-	O
gauge	O
needle	O
.	O

An	O
equal	O
volume	O
of	O
thrombin	B-GP
solution	O
was	O
immediately	O
injected	O
at	O
the	O
same	O
site	O
,	O
where	O
the	O
injected	O
cells	O
will	O
be	O
placed	O
within	O
the	O
fibrin	B-GP
gel	O
.	O

Animals	B-OG
were	O
euthanized	O
1	O
week	O
after	O
the	O
final	O
injection	O
.	O

To	O
determine	O
efficiency	O
of	O
progressive	O
cell	O
injection	O
,	O
the	O
volume	O
of	O
implant	O
after	O
4	O
injections	O
was	O
evaluated	O
and	O
the	O
measured	O
volume	O
was	O
compared	O
with	O
that	O
by	O
single	O
injection	O
of	O
cells	O
.	O

For	O
the	O
single	O
injection	O
,	O
600	O
μl	O
of	O
fibrinogen	B-GP
solution	O
with	O
cells	O
and	O
600	O
μl	O
of	O
thrombin	B-GP
solution	O
were	O
injected	O
,	O
of	O
which	O
number	O
of	O
cells	O
is	O
equal	O
to	O
the	O
total	O
number	O
of	O
4	O
injections	O
.	O

The	O
single	O
or	O
progressive	O
injection	O
group	O
was	O
euthanized	O
4	O
weeks	O
after	O
injection	O
or	O
1	O
week	O
after	O
the	O
4th	O
injection	O
,	O
respectively	O
.	O

Implant	O
volume	O
was	O
measured	O
by	O
water	O
displacement	O
method	O
,	O
then	O
implant	O
was	O
evaluated	O
by	O
histological	O
and	O
immunohistological	O
analysis43	O
.	O

VML	O
injury	B-DS
model	O
and	O
cells	O
injection	O

The	O
VML	O
injury	B-DS
model	O
was	O
created	O
in	O
nude	B-OG
rats	I-OG
(	O
male	O
,	O
12	O
–	O
14	O
weeks	O
old	O
,	O
Charles	O
River	O
Laboratory	O
)	O
36	O
.	O

Under	O
anesthesia	O
,	O
the	O
fascia	O
was	O
separated	O
from	O
the	O
TA	O
muscle	O
,	O
and	O
then	O
approximately	O
30	O
%	O
of	O
middle	O
third	O
TA	O
muscle	O
was	O
excised	O
.	O

The	O
excised	O
TA	O
muscle	O
weight	O
was	O
estimated	O
by	O
following	O
using	O
the	O
equation	O
:	O
y	O
(	O
g	O
)	O
=	O
0	O
.	O
0017	O
×	O
body	O
weight	O
(	O
g	O
)	O
–	O
0	O
.	O
0716	O
.	O

In	O
addition	O
to	O
the	O
TA	O
muscle	O
excision	O
,	O
extensor	O
digitorum	O
longus	O
(	O
EDL	O
)	O
and	O
extensor	O
hallucis	O
longus	O
(	O
EHL	O
)	O
muscles	O
were	O
removed	O
to	O
exclude	O
compensatory	O
hypertrophy	O
during	O
muscle	O
regeneration	O
following	O
TA	O
excision	O
.	O

The	O
remaining	O
TA	O
muscle	O
was	O
covered	O
with	O
fascia	O
and	O
skin	O
was	O
closed	O
using	O
sutures	O
and	O
surgical	O
glue	O
.	O

Fibrin	B-GP
gels	O
with	O
or	O
without	O
cells	O
were	O
injected	O
into	O
the	O
defect	O
sites	O
.	O

In	O
this	O
study	O
,	O
7	O
groups	O
were	O
investigated	O
(	O
n	O
=	O
4	O
per	O
group	O
,	O
total	O
28	O
rats	B-OG
);	O
(	O
1	O
)	O
normal	O
(	O
age	O
-	O
matched	O
control	O
),	O
(	O
2	O
)	O
no	O
treatment	O
(	O
defect	O
only	O
),	O
(	O
3	O
)	O
multiple	O
injection	O
-	O
gel	O
only	O
,	O
(	O
4	O
)	O
single	O
injection	O
-	O
C2C12	O
,	O
(	O
5	O
),	O
progressive	O
injection	O
-	O
C2C12	O
,	O
(	O
6	O
)	O
single	O
injection	O
-	O
hMPC	O
,	O
(	O
7	O
)	O
progressive	O
injection	O
-	O
hMPC	O
.	O

For	O
a	O
single	O
injection	O
,	O
300	O
μl	O
of	O
fibrinogen	B-GP
solution	O
with	O
cells	O
was	O
delivered	O
into	O
the	O
defect	O
sites	O
with	O
a	O
26	O
-	O
gauge	O
needle	O
followed	O
immediately	O
by	O
an	O
additional	O
injection	O
of	O
300	O
μl	O
of	O
thrombin	B-GP
solution	O
at	O
the	O
same	O
injection	O
site	O
to	O
form	O
fibrin	B-GP
gel	O
(	O
total	O
injection	O
volume	O
=	O
600	O
μl	O
).	O

The	O
volume	O
of	O
600	O
μl	O
filled	O
the	O
defect	O
in	O
the	O
TA	O
muscle	O
.	O

For	O
multiple	O
and	O
progressive	O
injections	O
,	O
4	O
cell	O
injections	O
were	O
performed	O
every	O
week	O
.	O

The	O
first	O
injection	O
was	O
performed	O
with	O
a	O
total	O
volume	O
of	O
300	O
μl	O
and	O
subsequent	O
three	O
injections	O
were	O
done	O
with	O
a	O
volume	O
of	O
100	O
μl	O
per	O
injection	O
.	O

To	O
track	O
the	O
injected	O
cells	O
within	O
the	O
TA	O
muscle	O
,	O
C2C12	O
cells	O
were	O
labeled	O
with	O
DiI	O
(	O
Vybrant	O
®	O
Multicolor	O
Cell	O
-	O
Labeling	O
Kit	O
,	O
Thermo	O
Scientific	O
,	O
Inc	O
.)	O
for	O
the	O
1st	O
and	O
4th	O
injections	O
and	O
co	O
-	O
labeling	O
of	O
DiI	O
and	O
GFP	B-GP
was	O
used	O
to	O
identify	O
the	O
injected	O
C2C12	O
cells	O
within	O
the	O
TA	O
defect	O
.	O

In	O
vivo	O
functional	O
analysis	O
of	O
TA	O
muscle	O

To	O
examine	O
restoration	O
of	O
muscle	O
function	O
,	O
tetanic	O
force	O
of	O
TA	O
muscle	O
was	O
measured	O
at	O
4	O
weeks	O
after	O
surgery	O
(	O
1	O
week	O
after	O
4th	O
injection	O
in	O
the	O
multiple	O
and	O
progressive	O
injection	O
).	O

Anterior	O
crural	O
muscle	O
in	O
vivo	O
mechanical	O
properties	O
were	O
analyzed	O
with	O
the	O
dual	O
-	O
mode	O
muscle	O
lever	O
system	O
(	O
Aurora	O
Scientific	O
,	O
Inc	O
.,	O
Mod	O
,	O
305b	O
,	O
Aurora	O
,	O
Canada	O
)	O
36	O
.	O

The	O
foot	O
to	O
be	O
measured	O
was	O
attached	O
to	O
a	O
foot	O
plate	O
and	O
knee	O
and	O
ankle	O
were	O
positioned	O
at	O
90	O
-	O
degree	O
angle	O
.	O

Tetanic	O
analysis	O
was	O
performed	O
by	O
stimulating	O
the	O
peroneal	O
nerve	O
using	O
a	O
Grass	O
stimulator	O
(	O
S88	O
)	O
at	O
100	O
Hz	O
with	O
a	O
pulse	O
-	O
width	O
of	O
0	O
.	O
1	O
msec	O
and	O
10	O
V	O
.	O

Muscle	O
force	O
(	O
N	O
Kg	O
−	O
1	O
)	O
was	O
calculated	O
by	O
peak	O
isometric	O
torque	O
per	O
body	O
weight	O
(	O
n	O
=	O
4	O
per	O
group	O
).	O

After	O
the	O
functional	O
assessment	O
and	O
harvesting	O
of	O
TA	O
muscle	O
,	O
the	O
retrieved	O
TA	O
muscle	O
tissue	O
was	O
weighed	O
and	O
processed	O
for	O
histological	O
analysis	O
.	O

The	O
percentage	O
of	O
muscle	O
mass	O
was	O
calculated	O
by	O
the	O
ratio	O
of	O
the	O
weight	O
of	O
injured	O
TA	O
muscle	O
to	O
that	O
of	O
contralateral	O
TA	O
muscle	O
(	O
n	O
=	O
4	O
per	O
group	O
).	O

Histological	O
and	O
immunofluorescent	O
analysis	O

The	O
harvested	O
TA	O
muscles	O
were	O
freshly	O
frozen	O
in	O
liquid	O
nitrogen	O
immediately	O
for	O
cryo	O
-	O
embedding	O
or	O
fixed	O
with	O
4	O
%	O
paraformaldehyde	O
for	O
paraffin	O
embedding	O
.	O

For	O
histological	O
evaluations	O
,	O
H	O
&	O
E	O
staining	O
and	O
MT	O
staining	O
were	O
performed	O
on	O
the	O
tissue	O
sections	O
.	O

To	O
evaluate	O
TA	O
muscle	O
thickness	O
of	O
each	O
group	O
,	O
three	O
different	O
regions	O
in	O
the	O
middle	O
of	O
the	O
TA	O
muscles	O
in	O
the	O
H	O
&	O
E	O
images	O
were	O
chosen	O
and	O
the	O
thickness	O
was	O
measured	O
(	O
n	O
=	O
4	O
of	O
each	O
per	O
group	O
)	O
in	O
blinded	O
fashion	O
.	O

For	O
immunostaining	O
,	O
the	O
cryosections	O
(	O
7	O
μm	O
)	O
were	O
fixed	O
with	O
4	O
%	O
paraformaldehyde	O
.	O

Paraffin	O
sections	O
(	O
5	O
μm	O
)	O
were	O
deparaffinized	O
and	O
processed	O
for	O
antigen	O
retrieval	O
with	O
the	O
heat	O
-	O
induced	O
process	O
using	O
sodium	O
citrate	O
buffer	O
.	O

Tissue	O
sections	O
were	O
incubated	O
with	O
methanol	O
at	O
−	O
20	O
°	O
C	O
for	O
10	O
minutes	O
,	O
acetone	O
at	O
room	O
temperature	O
for	O
7	O
minutes	O
or	O
0	O
.	O
2	O
%	O
Triton	O
X	O
-	O
100	O
for	O
30	O
minutes	O
at	O
room	O
temperature	O
for	O
permeabilization	O
,	O
and	O
then	O
blocked	O
using	O
a	O
serum	O
-	O
free	O
blocking	O
agent	O
(	O
X090930	O
-	O
1	O
;	O
Dako	O
,	O
Carpentaria	O
,	O
CA	O
)	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O

All	O
antibodies	O
were	O
diluted	O
with	O
antibody	O
diluent	O
(	O
S302283	O
-	O
1	O
;	O
Dako	O
),	O
and	O
the	O
blocked	O
sections	O
were	O
incubated	O
with	O
primary	O
antibodies	O
at	O
room	O
temperature	O
for	O
1	O
h	O
or	O
incubated	O
at	O
4	O
°	O
C	O
for	O
overnight	O
.	O

Secondary	O
antibodies	O
such	O
as	O
Alexa	O
488	O
-	O
conjugated	O
anti	O
-	O
mouse	B-OG
or	O
anti	O
-	O
rabbit	B-OG
antibody	O
(	O
A11017	O
;	O
A11070	O
;	O
1	O
:	O
200	O
dilution	O
;	O
Invitrogen	O
,	O
Eugene	O
,	O
OR	O
),	O
Texas	O
Red	O
-	O
conjugated	O
anti	O
-	O
mouse	B-OG
,	O
anti	O
-	O
rabbit	B-OG
,	O
or	O
anti	O
-	O
rat	B-OG
antibody	O
(	O
TI	O
-	O
2000	O
;	O
TI	O
-	O
1000	O
;	O
TI	O
-	O
9400	O
;	O
1	O
:	O
200	O
dilution	O
;	O
Vector	O
Labs	O
,	O
Burlingame	O
,	O
CA	O
),	O
or	O
Cy5	O
-	O
conjugated	O
anti	O
-	O
mouse	B-OG
or	O
anti	O
-	O
rabbit	B-OG
antibody	O
(	O
A10524	O
;	O
A10523	O
;	O
1	O
:	O
200	O
dilution	O
;	O
Invitrogen	O
)	O
were	O
treated	O
at	O
room	O
temperature	O
for	O
40	O
min	O
.	O

Tissue	O
sections	O
were	O
then	O
mounted	O
with	O
VECTASHIELD	O
Mounting	O
Media	O
with	O
DAPI	O
(	O
H	O
-	O
1200	O
;	O
Vector	O
Labs	O
)	O
and	O
analyzed	O
by	O
fluorescent	O
imaging	O
using	O
an	O
upright	O
(	O
LEICA	O
)	O
and	O
confocal	O
microscope	O
(	O
Olympus	O
).	O

To	O
identify	O
the	O
injected	O
GFP	B-GP
+	O
-	O
C2C12	O
cells	O
,	O
the	O
sections	O
were	O
incubated	O
with	O
mouse	B-OG
anti	O
-	O
GFP	B-GP
antibody	O
(	O
sc	O
-	O
9996	O
;	O
1	O
:	O
100	O
dilution	O
;	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Santa	O
Cruz	O
,	O
CA	O
)	O
or	O
rabbit	B-OG
anti	O
-	O
GFP	B-GP
antibody	O
(	O
ab290	O
;	O
1	O
:	O
500	O
dilution	O
;	O
Abcam	O
,	O
Cambridge	O
,	O
MA	O
).	O

For	O
hMPC	O
tracking	O
,	O
tissues	O
were	O
stained	O
with	O
rabbit	B-OG
anti	O
-	O
HLA	B-GP
A	I-GP
(	O
ab52922	O
;	O
1	O
:	O
100	O
dilution	O
;	O
Abcam	O
)	O
or	O
mouse	B-OG
anti	O
-	O
HNA	B-GP
(	O
MAB1281	O
;	O
1	O
:	O
100	O
dilution	O
;	O
EMD	O
Millipore	O
,	O
Darmstadt	O
,	O
Germany	O
).	O

Muscle	O
differentiation	O
was	O
examined	O
by	O
immunostaining	O
for	O
mouse	B-OG
anti	O
-	O
MHC	B-GP
(	O
MF20	O
;	O
1	O
:	O
30	O
dilution	O
;	O
Developmental	O
Studies	O
Hybridoma	O
Bank	O
,	O
Iowa	O
City	O
,	O
IA	O
)	O
or	O
mouse	B-OG
or	O
rabbit	B-OG
anti	O
-	O
Myogenin	B-GP
(	O
ab1835	O
;	O
1	O
:	O
100	O
dilution	O
,	O
ab124800	O
;	O
1	O
:	O
200	O
Abcam	O
).	O

Cells	O
proliferation	O
was	O
estimated	O
by	O
immunostaining	O
for	O
mouse	B-OG
or	O
rabbit	B-OG
anti	O
-	O
PCNA	B-GP
(	O
ab29	O
;	O
1	O
:	O
500	O
dilution	O
,	O
ab18197	O
;	O
1	O
:	O
1000	O
dilution	O
,	O
Abcam	O
).	O

To	O
evaluate	O
muscle	O
fibrosis	O
,	O
tissue	O
sections	O
were	O
stained	O
with	O
rabbit	B-OG
anti	O
-	O
collagen	B-GP
I	I-GP
(	O
ab34710	O
;	O
1	O
:	O
200	O
dilution	O
;	O
Abcam	O
).	O

For	O
vascular	O
integration	O
,	O
the	O
tissue	O
sections	O
were	O
stained	O
with	O
rabbit	B-OG
anti	O
-	O
vWF	B-GP
(	O
A0082	O
;	O
1	O
:	O
400	O
dilution	O
;	O
DAKO	O
)	O
and	O
mouse	B-OG
anti	O
-	O
α	B-GP
-	I-GP
SMA	I-GP
(	O
sc	O
-	O
32251	O
;	O
1	O
:	O
50	O
dilution	O
;	O
Santa	O
Cruz	O
).	O

Neuronal	O
ingrowth	O
was	O
visualized	O
by	O
immunostaining	O
with	O
rabbit	B-OG
anti	O
-	O
NF	B-GP
(	O
N4142	O
;	O
NF200	O
,	O
1	O
:	O
80	O
dilution	O
;	O
Sigma	O
)	O
and	O
rat	B-OG
anti	O
-	O
AChR	B-GP
(	O
ab24719	O
;	O
1	O
:	O
100	O
dilution	O
;	O
Abcam	O
).	O

To	O
evaluate	O
vascularization	O
and	O
the	O
vascular	O
maturation	O
,	O
vWF	B-GP
/	O
α	B-GP
-	I-GP
SMA	I-GP
double	O
immunostaining	O
was	O
performed	O
and	O
using	O
3	O
to	O
5	O
randomly	O
selected	O
images	O
from	O
each	O
injected	O
regions	O
of	O
the	O
retrieved	O
tissues	O
(	O
x400	O
magnification	O
,	O
n	O
=	O
4	O
per	O
group	O
)	O
44	O
.	O

The	O
number	O
of	O
vWF	B-GP
+	O
vessels	O
(	O
per	O
field	O
of	O
400x	O
magnified	O
image	O
),	O
area	O
of	O
vWF	B-GP
+	O
vessels	O
(	O
μm2	O
per	O
field	O
of	O
400x	O
magnified	O
image	O
),	O
and	O
percentage	O
of	O
each	O
size	O
of	O
vessels	O
were	O
quantified	O
and	O
the	O
maturation	O
index	O
(%)	O
was	O
determined	O
as	O
the	O
ratio	O
of	O
α	B-GP
-	I-GP
SMA	I-GP
+	O
vessels	O
to	O
the	O
total	O
number	O
of	O
vessels4546	O
.	O

Blood	O
vessels	O
were	O
quantitatively	O
analyzed	O
with	O
image	O
analysis	O
software	O
(	O
Image	O
J	O
)	O
in	O
blinded	O
fashion	O
.	O

To	O
identify	O
whether	O
the	O
infused	O
cells	O
contributed	O
to	O
formation	O
of	O
muscle	O
fibers	O
in	O
vivo	O
,	O
GFP	B-GP
/	O
MHC	B-GP
and	O
HLA	B-GP
/	O
MHC	B-GP
staining	O
was	O
performed	O
on	O
the	O
GFP	B-GP
+	O
-	O
C2C12	O
-	O
and	O
hMPC	O
-	O
injected	O
TA	O
muscles	O
,	O
respectively	O
.	O

Double	O
positive	O
staining	O
in	O
the	O
fluorescent	O
images	O
was	O
considered	O
to	O
be	O
a	O
contribution	O
of	O
the	O
injected	O
cells	O
in	O
the	O
muscle	O
fiber	O
formation	O
.	O

Myogenesis	O
of	O
injected	O
cells	O
were	O
also	O
identified	O
by	O
Myogenin	B-GP
+/	O
DiI	O
-	O
labeled	O
cells	O
in	O
C2C12	O
-	O
injected	O
TA	O
muscles	O
and	O
Myogenin	B-GP
+/	O
HNA	B-GP
+	O
cells	O
in	O
hMPC	O
-	O
injected	O
TA	O
muscles	O
(	O
x400	O
magnification	O
,	O
n	O
=	O
3	O
–	O
4	O
per	O
group	O
,	O
3	O
–	O
5	O
fields	O
per	O
each	O
sample	O
).	O

Proliferation	O
of	O
injected	O
C2C12	O
and	O
hMPCs	O
were	O
evaluated	O
by	O
double	O
positive	O
of	O
PCNA	B-GP
/	O
DiI	O
-	O
labeled	O
cells	O
in	O
C2C12	O
-	O
injected	O
TA	O
muscles	O
and	O
PCNA	B-GP
/	O
HNA	B-GP
cells	O
in	O
hMPC	O
-	O
injected	O
TA	O
muscles	O
(	O
x400	O
magnification	O
,	O
n	O
=	O
3	O
–	O
4	O
per	O
group	O
,	O
3	O
–	O
5	O
fields	O
per	O
each	O
sample	O
).	O

TA	O
muscle	O
fibrosis	O
of	O
inner	O
and	O
outer	O
area	O
was	O
quantified	O
by	O
percentage	O
of	O
collagen	B-GP
I	I-GP
positive	O
area	O
in	O
the	O
fluorescent	O
images	O
of	O
collagen	B-GP
I	I-GP
/	O
MHC	B-GP
staining	O
(	O
x200	O
magnification	O
,	O
n	O
=	O
4	O
per	O
group	O
,	O
3	O
fields	O
of	O
each	O
area	O
per	O
each	O
sample	O
).	O

Statistical	O
analysis	O

Results	O
were	O
analyzed	O
with	O
Origin	O
Pro	O
8	O
.	O
5	O
(	O
OriginLab	O
Co	O
,	O
Northampton	O
,	O
MA	O
,	O
USA	O
)	O
and	O
SPSS	O
software	O
(	O
SPSS	O
,	O
version	O
19	O
;	O
IBM	O
,	O
Armonk	O
,	O
NY	O
).	O

One	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
),	O
Tukey	O
post	O
hoc	O
testing	O
and	O
Student	O
’	O
s	O
t	O
-	O
test	O
were	O
applied	O
to	O
mean	O
comparisons	O
.	O

Variables	O
are	O
expressed	O
as	O
mean	O
±	O
standard	O
deviation	O
,	O
and	O
differences	O
were	O
considered	O
significant	O
at	O
P	O
<	O
0	O
.	O
05	O
.	O

Additional	O
Information	O

How	O
to	O
cite	O
this	O
article	O
:	O
Kim	O
,	O
J	O
.	O

H	O
.	O
et	O
al	O
.	O

Progressive	O
Muscle	O
Cell	O
Delivery	O
as	O
a	O
Solution	O
for	O
Volumetric	O
Muscle	O
Defect	O
Repair	O
.	O
Sci	O
.	O

Rep	O
.	O
6	O
,	O
38754	O
;	O
doi	O
:	O
10	O
.	O
1038	O
/	O
srep38754	O
(	O
2016	O
).	O

Publisher	O
'	O
s	O
note	O
:	O
Springer	O
Nature	O
remains	O
neutral	O
with	O
regard	O
to	O
jurisdictional	O
claims	O
in	O
published	O
maps	O
and	O
institutional	O
affiliations	O
.	O

Supplementary	O
Material	O

Supplementary	O
Information	O

Author	O
Contributions	O
J	O
.	O
H	O
.	O
K	O
.,	O
I	O
.	O
K	O
.	O
K	O
.,	O
J	O
.	O
J	O
.	O
Y	O
.	O
and	O
A	O
.	O
A	O
.	O
designed	O
experiments	O
.	O

J	O
.	O
H	O
.	O
K	O
.	O
and	O
I	O
.	O
K	O
.	O
K	O
.	O
performed	O
data	O
acquisition	O
,	O
analysis	O
and	O
interpretation	O
and	O
wrote	O
the	O
manuscript	O
.	O

All	O
authors	O
discussed	O
the	O
results	O
and	O
reviewed	O
the	O
manuscript	O
.	O

(	O
a	O
)	O
Multiple	O
cells	O
in	O
gel	O
or	O
gel	O
only	O
injections	O
in	O
a	O
progressive	O
manner	O
were	O
performed	O
with	O
athymic	O
mice	O
and	O
the	O
volume	O
of	O
implant	O
was	O
measured	O
by	O
injection	O
time	O
(	O
2	O
,	O
4	O
,	O
6	O
,	O
and	O
8	O
injections	O
).	O

Each	O
injection	O
of	O
GFP	O
+	O
-	O
C2C12	O
was	O
performed	O
once	O
in	O
a	O
week	O
with	O
the	O
equal	O
volume	O
of	O
cells	O
in	O
gel	O
or	O
gel	O
only	O
.	O

ANOVA	O
,	O
Tukey	O
test	O
(	O
n	O
=	O
3	O
–	O
4	O
).	O
*	O
P	O
<	O
0	O
.	O
0001	O
with	O
2	O
times	O
of	O
progressive	O
cell	O
injection	O
,	O
†	O
P	O
<	O
0	O
.	O
003	O
with	O
4	O
times	O
of	O
progressive	O
cell	O
injection	O
,	O
‡	O
P	O
<	O
0	O
.	O
001	O
with	O
2	O
times	O
of	O
gel	O
only	O
injection	O
.	O

(	O
b	O
,	O
c	O
)	O
The	O
efficacy	O
of	O
progressive	O
cell	O
delivery	O
was	O
compared	O
with	O
single	O
cell	O
delivery	O
for	O
implanted	O
cells	O
survival	O
and	O
volumetric	O
tissue	O
construction	O
.	O

Total	O
injected	O
volume	O
of	O
4	O
-	O
progressive	O
cells	O
in	O
gel	O
injection	O
was	O
same	O
as	O
that	O
of	O
single	O
injection	O
.	O

Volume	O
of	O
implant	O
(	O
mm2	O
)	O
of	O
single	O
and	O
4	O
-	O
progressive	O
injection	O
was	O
compared	O
in	O
(	O
b	O
).	O

Student	O
’	O
s	O
t	O
-	O
test	O
(	O
n	O
=	O
4	O
).	O
*	O
P	O
<	O
0	O
.	O
0001	O
with	O
single	O
cells	O
in	O
gel	O
injection	O
.	O

Representative	O
H	O
&	O
E	O
images	O
of	O
single	O
and	O
progressive	O
cells	O
in	O
gel	O
injections	O
were	O
shown	O
in	O
upper	O
row	O
of	O
(	O
c	O
).	O

Scale	O
bars	O
,	O
1	O
mm	O
.	O

Implants	O
were	O
stained	O
for	O
GFP	O
(	O
green	O
)	O
to	O
identify	O
injected	O
cells	O
and	O
their	O
representative	O
images	O
were	O
shown	O
in	O
lower	O
row	O
of	O
(	O
c	O
).	O

Implanted	O
site	O
of	O
single	O
cells	O
in	O
gel	O
were	O
distinguished	O
by	O
white	O
dash	O
line	O
.	O

Scale	O
bars	O
,	O
200	O
μm	O
.	O

(	O
a	O
)	O
Representative	O
vWF	O
(	O
green	O
)/	O
α	O
-	O
SMA	O
(	O
red	O
)	O
staining	O
images	O
of	O
implants	O
constructed	O
by	O
single	O
injection	O
.	O

(	O
b	O
)	O
Representative	O
staining	O
images	O
of	O
implants	O
constructed	O
by	O
4	O
-	O
progressive	O
injection	O
.	O

MHC	O
(	O
red	O
)	O
in	O
the	O
first	O
row	O
,	O
GFP	O
(	O
green	O
)/	O
vWF	O
(	O
red	O
)	O
in	O
the	O
second	O
row	O
,	O
vWF	O
(	O
green	O
)/	O
α	O
-	O
SMA	O
(	O
red	O
)	O
in	O
the	O
third	O
row	O
,	O
NF	O
(	O
green	O
)/	O
AChR	O
(	O
red	O
)	O
in	O
the	O
fourth	O
row	O
.	O

Low	O
magnification	O
images	O
of	O
implants	O
were	O
shown	O
in	O
left	O
column	O
.	O

Scale	O
bars	O
,	O
200	O
μm	O
.	O

High	O
magnification	O
images	O
of	O
the	O
firstly	O
,	O
secondary	O
and	O
thirdly	O
,	O
and	O
fourthly	O
injected	O
areas	O
were	O
shown	O
in	O
second	O
,	O
third	O
and	O
fourth	O
columns	O
,	O
respectively	O
.	O

Scale	O
bars	O
,	O
50	O
μm	O
(	O
x400	O
magnification	O
).	O

(	O
c	O
,	O
d	O
)	O
In	O
-	O
vivo	O
vascularization	O
of	O
single	O
injection	O
vs	O
progressive	O
injection	O
(	O
c	O
)	O
and	O
each	O
injected	O
area	O
in	O
progressive	O
injection	O
(	O
d	O
)	O
was	O
evaluated	O
with	O
staining	O
images	O
for	O
vWF	O
/	O
α	O
-	O
SMA	O
(	O
x400	O
magnification	O
)	O
in	O
aspects	O
of	O
number	O
of	O
vWF	O
+	O
vessels	O
(	O
per	O
field	O
,	O
i	O
),	O
area	O
of	O
vWF	O
+	O
vessels	O
(	O
μm2	O
per	O
field	O
,	O
ii	O
),	O
maturation	O
index	O
(%,	O
iii	O
)	O
and	O
percentage	O
of	O
each	O
size	O
of	O
vessels	O
(	O
iv	O
).	O

Maturation	O
index	O
(%)	O
=	O
α	O
-	O
SMA	O
+	O
vessels	O
/	O
total	O
vessels	O
×	O
100	O
.	O

(	O
c	O
)	O
Student	O
’	O
s	O
t	O
-	O
test	O
(	O
n	O
=	O
4	O
,	O
3	O
–	O
4	O
fields	O
of	O
each	O
sample	O
),	O
*	O
P	O
<	O
0	O
.	O
05	O
with	O
single	O
injection	O
.	O

(	O
d	O
)	O
ANOVA	O
,	O
Tukey	O
test	O
(	O
n	O
=	O
4	O
,	O
3	O
–	O
5	O
fields	O
per	O
each	O
area	O
in	O
each	O
sample	O
).	O
*	O
P	O
<	O
0	O
.	O
05	O
with	O
the	O
1st	O
injection	O
,	O
†	O
P	O
<	O
0	O
.	O
05	O
with	O
the	O
2nd	O
–	O
3rd	O
injection	O
.	O

Tibialis	O
anterior	O
(	O
TA	O
)	O
muscle	O
injury	O
was	O
created	O
in	O
nude	O
rats	O
and	O
4	O
-	O
progressive	O
injection	O
of	O
C2C12	O
(	O
a	O
,	O
b	O
)	O
and	O
hMPCs	O
(	O
c	O
,	O
d	O
)	O
were	O
performed	O
.	O

The	O
TA	O
muscles	O
were	O
harvested	O
at	O
1	O
week	O
after	O
the	O
fourth	O
injection	O
.	O

(	O
a	O
,	O
c	O
)	O
TA	O
muscle	O
mass	O
(	O
defected	O
TA	O
per	O
Contralateral	O
TA	O
)	O
and	O
muscle	O
force	O
(	O
N	O
Kg	O
−	O
1	O
)	O
of	O
C2C12	O
injection	O
in	O
(	O
a	O
)	O
and	O
hMPC	O
injection	O
in	O
(	O
c	O
).	O

(	O
b	O
,	O
d	O
)	O
Representative	O
H	O
&	O
E	O
and	O
masson	O
’	O
s	O
trichrome	O
staining	O
images	O
and	O
TA	O
muscle	O
thickness	O
(	O
mm	O
)	O
of	O
C2C12	O
injection	O
in	O
(	O
b	O
)	O
and	O
hMPC	O
injection	O
in	O
(	O
d	O
).	O

The	O
TA	O
muscle	O
thickness	O
(	O
mm	O
)	O
was	O
measured	O
by	O
using	O
H	O
&	O
E	O
staining	O
images	O
.	O

Three	O
different	O
injected	O
areas	O
of	O
the	O
TA	O
per	O
sample	O
were	O
chosen	O
to	O
measure	O
the	O
TA	O
muscle	O
thickness	O
.	O

H	O
&	O
E	O
staining	O
images	O
in	O
upper	O
row	O
.	O

Masson	O
’	O
s	O
trichrome	O
staining	O
images	O
in	O
lower	O
row	O
.	O

Scale	O
bars	O
,	O
500	O
μm	O
.	O

(	O
a	O
)	O
ANOVA	O
,	O
Tukey	O
test	O
(	O
n	O
=	O
4	O
).	O

In	O
TA	O
muscle	O
mass	O
,	O
*	O
P	O
<	O
0	O
.	O
05	O
with	O
Normal	O
,	O
†	O
P	O
<	O
0	O
.	O
001	O
with	O
No	O
treatment	O
,	O
‡	O
P	O
<	O
0	O
.	O
001	O
with	O
Gel	O
only	O
,	O
§	O
P	O
<	O
0	O
.	O
017	O
with	O
Single	O
C2C12	O
.	O

In	O
muscle	O
function	O
,	O
*	O
P	O
<	O
0	O
.	O
001	O
with	O
Normal	O
,	O
†	O
P	O
<	O
0	O
.	O
015	O
with	O
No	O
treatment	O
,	O
‡	O
P	O
<	O
0	O
.	O
045	O
with	O
Gel	O
only	O
,	O
§	O
P	O
<	O
0	O
.	O
016	O
with	O
Single	O
C2C12	O
.	O

(	O
b	O
)	O
ANOVA	O
,	O
Tukey	O
test	O
(	O
n	O
=	O
4	O
).	O
*	O
P	O
<	O
0	O
.	O
001	O
with	O
Normal	O
,	O
†	O
P	O
<	O
0	O
.	O
001	O
with	O
No	O
treatment	O
,	O
‡	O
P	O
<	O
0	O
.	O
003	O
with	O
Gel	O
only	O
,	O
§	O
P	O
<	O
0	O
.	O
001	O
with	O
Single	O
C2C12	O
.	O

(	O
c	O
)	O
Student	O
’	O
s	O
t	O
-	O
test	O
(	O
n	O
=	O
4	O
).	O
*	O
P	O
<	O
0	O
.	O
045	O
with	O
Single	O
hMPC	O
in	O
TA	O
muscle	O
mass	O
,	O
*	O
P	O
<	O
0	O
.	O
038	O
with	O
Single	O
hMPC	O
in	O
muscle	O
function	O
.	O

(	O
d	O
)	O
Student	O
’	O
s	O
t	O
-	O
test	O
(	O
n	O
=	O
4	O
).	O
*	O
P	O
<	O
0	O
.	O
003	O
with	O
Single	O
hMPC	O
.	O

(	O
a	O
)	O
Representative	O
staining	O
images	O
of	O
single	O
-	O
C2C12	O
and	O
progressive	O
-	O
C2C12	O
injected	O
TA	O
muscles	O
.	O

For	O
both	O
single	O
and	O
progressive	O
injection	O
,	O
GFP	O
+	O
-	O
C2C12	O
was	O
injected	O
and	O
identified	O
by	O
staining	O
for	O
GFP	O
(	O
green	O
).	O

Myotubes	O
or	O
myofibers	O
were	O
stained	O
for	O
MHC	O
(	O
grey	O
).	O

GFP	O
+	O
-	O
C2C12	O
was	O
labeled	O
with	O
DiI	O
(	O
red	O
)	O
in	O
single	O
-	O
C2C12	O
injection	O
.	O

In	O
progressive	O
-	O
C2C12	O
injection	O
,	O
the	O
firstly	O
and	O
fourthly	O
injected	O
GFP	O
+	O
-	O
C2C12	O
were	O
labeled	O
with	O
DiI	O
(	O
red	O
).	O

Yellow	O
arrows	O
,	O
GFP	O
+/	O
DiI	O
+	O
cells	O
.	O

White	O
arrows	O
,	O
MHC	O
+/	O
GFP	O
+/	O
DiI	O
+	O
cells	O
.	O

White	O
arrowheads	O
,	O
MHC	O
-/	O
GFP	O
+/	O
DiI	O
+	O
cells	O
.	O

(	O
b	O
)	O
Representative	O
staining	O
images	O
of	O
single	O
-	O
hMPC	O
and	O
progressive	O
-	O
hMPC	O
injected	O
TA	O
muscles	O
.	O

Injected	O
hMPC	O
were	O
identified	O
by	O
HLA	O
staining	O
(	O
red	O
)	O
and	O
myotubes	O
or	O
myofibers	O
were	O
stained	O
for	O
MHC	O
(	O
green	O
).	O

White	O
arrows	O
,	O
MHC	O
+/	O
HLA	O
+	O
cells	O
.	O

(	O
a	O
,	O
b	O
)	O
Scale	O
bars	O
,	O
500	O
μm	O
in	O
left	O
column	O
and	O
50	O
μm	O
in	O
middle	O
and	O
right	O
columns	O
.	O

(	O
a	O
)	O
Representative	O
vWF	O
(	O
green	O
)/	O
α	O
-	O
SMA	O
(	O
red	O
)	O
staining	O
images	O
of	O
hMPCs	O
-	O
injected	O
TA	O
muscles	O
.	O

Low	O
magnification	O
images	O
of	O
implants	O
were	O
shown	O
in	O
upper	O
row	O
.	O

Scale	O
bars	O
,	O
200	O
μm	O
.	O

High	O
magnification	O
images	O
of	O
inner	O
and	O
outer	O
TA	O
muscles	O
were	O
shown	O
in	O
middle	O
and	O
lower	O
rows	O
,	O
respectively	O
.	O

Scale	O
bars	O
,	O
50	O
μm	O
(	O
x400	O
magnification	O
).	O

(	O
b	O
–	O
e	O
)	O
Vascularization	O
of	O
each	O
group	O
was	O
quantified	O
with	O
staining	O
images	O
for	O
vWF	O
/	O
α	O
-	O
SMA	O
(	O
x400	O
magnification	O
)	O
in	O
terms	O
of	O
number	O
of	O
vWF	O
+	O
vessels	O
(	O
per	O
field	O
,	O
b	O
),	O
area	O
of	O
vWF	O
+	O
vessels	O
(	O
μm2	O
per	O
field	O
,	O
c	O
),	O
maturation	O
index	O
(%,	O
d	O
)	O
and	O
percentage	O
of	O
each	O
size	O
of	O
vessels	O
(	O
e	O
).	O

Maturation	O
index	O
(%)	O
=	O
α	O
-	O
SMA	O
+	O
vessels	O
/	O
total	O
vessels	O
×	O
100	O
.	O

ANOVA	O
,	O
Tukey	O
test	O
(	O
n	O
=	O
4	O
,	O
6	O
–	O
10	O
fields	O
of	O
each	O
sample	O
).	O
*	O
P	O
<	O
0	O
.	O
018	O
with	O
Normal	O
,	O
†	O
P	O
<	O
0	O
.	O
001	O
with	O
No	O
treatment	O
,	O
‡	O
P	O
<	O
0	O
.	O
001	O
with	O
Gel	O
only	O
,	O
§	O
P	O
<	O
0	O
.	O
001	O
with	O
Single	O
hMPCs	O
.	O

